All conditions

Melanoma

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

2389
Trials on record
325
Recruiting now
34
Australian sites
26
Phase 3 trials
11
PBS medicines
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Melanoma →

Get alerts when Melanoma trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Melanoma

Melanoma is a type of skin cancer that starts in the cells that give your skin its colour, called melanocytes. When these cells begin to grow and divide in an uncontrolled way, they can form a cancerous growth, most often on the skin but sometimes in the eye or other areas of the body. Melanoma is considered the most serious form of skin cancer because it can spread to other parts of the body if not caught and treated early.

Australia has one of the highest rates of melanoma in the world, largely because of the country's sunny climate and historically high levels of UV exposure. It is estimated that around 16,000 Australians are diagnosed with melanoma each year, and while it can affect anyone, it is more common in people with fair skin, a history of sunburn, or a large number of moles. It becomes more common as people get older, though younger adults can be diagnosed too.

Treatment depends on how far the melanoma has developed and whether it has spread beyond the original site. For melanomas caught at an early stage, surgery to remove the affected area of skin is the most common approach. When the cancer has spread further, doctors may consider options such as immunotherapy, targeted therapy, radiation, or a combination of these. A team of specialists will typically work together to assess your situation and explain what options may be suitable for you. It is always a good idea to ask your medical team questions so you feel informed and clear about what to expect.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Melanoma in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

PBS-subsidised medicines for Melanoma

11 medicines listed on the PBS for Melanoma. Filter by authority type, or open the full table below.

What the authority types mean Unrestricted: no clinical criteria; a doctor can prescribe it on the PBS for any appropriate use. Restricted benefit: subsidised only for the specific conditions or uses set out by the PBS. Streamlined authority: restricted, but the doctor does not need prior approval; they record a streamlined authority code confirming you meet the criteria. Authority required: restricted, and the doctor must get prior approval from Services Australia (by phone or online) before it is subsidised. Source: Pharmaceutical Benefits Scheme (pbs.gov.au).
Full PBS medicines table 11 listed

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. Prices shown are the PBS-determined dispensed price. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest.

Medicine Brand(s) Listed for
Binimetinib Mektovi malignant melanoma Unresectable Stage III or Stage IV AU$3526.68 Streamlined authority
Cobimetinib Cotellic malignant melanoma Unresectable Stage III or Stage IV AU$6872.51 Streamlined authority
Dabrafenib Tafinlar malignant melanoma Unresectable Stage III or Stage IV AU$4663.49 Streamlined authority
Encorafenib Braftovi malignant melanoma Unresectable Stage III or Stage IV AU$763.61 Streamlined authority
nivolumab + relatlimab Opdualag malignant melanoma Unresectable Stage III or Stage IV AU$9097.9 Streamlined authority
Pembrolizumab Keytruda malignant melanoma Unresectable Stage III or Stage IV AU$3632.56 Streamlined authority
Trametinib Mekinist malignant melanoma Unresectable Stage III or Stage IV AU$1748.81 Streamlined authority
Vemurafenib Zelboraf malignant melanoma Unresectable Stage III or Stage IV AU$1632.22 Streamlined authority
Dabrafenib Tafinlar malignant melanoma Resected Stage IIIB, Stage IIIC or Stage IIID AU$4663.49 Authority required
Pembrolizumab Keytruda malignant melanoma Resected Stage IIIB, Stage IIIC or Stage IIID AU$3632.56 Authority required
Trametinib Mekinist malignant melanoma Resected Stage IIIB, Stage IIIC or Stage IIID AU$1748.81 Authority required
Pembrolizumab Keytruda malignant melanoma Stage IIIB, Stage IIIC or Stage IIID AU$3632.56 Authority required
Nivolumab Opdivo malignant melanoma Stage IIIB, IIIC, IIID or Stage IV AU$1972.83 Authority required
Ipilimumab Yervoy melanoma Stage III AU$21378.52 Streamlined authority
tebentafusp Kimmtrak uveal melanoma Advanced (unresectable or metastatic) AU$17583.56 Authority required

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Research pipeline

Where trials for Melanoma currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Melanoma.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Melanoma by country. Australia is highlighted.

Showing the top 10 of 48 countries with trial sites.

Clinical trials for Melanoma

Showing 338 of 338 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT00405587 · Plexxikon Phase 1 · 2 countries Completed
Completed Phase 1 Est. completion 1 July 2015
🇦🇺 AU🇺🇸 US

**Who might be able to join this trial:** - You have a solid tumor that has been confirmed by a tissue test, and either it has stopped responding to standard treatments, or no standard or curative treatment exists for your condition. - If you are in a specific group requiring tissue samples (biopsies), you must have a...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01107418 · Hoffmann-La Roche Phase 1 · 2 countries Completed
Completed Phase 1 Est. completion 1 February 2013
🇦🇺 AU🇺🇸 US

Who might be able to join this trial: - You must be an adult aged 18 or older - You must have been diagnosed with advanced melanoma (a type of skin cancer) that has spread, classified as stage IIIc or stage IV - You must have already tried at least one standard treatment for your melanoma that did not work - Your tumor...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01584648 · Novartis Pharmaceuticals Phase 3 · 14 countries Completed
Completed Phase 3 Est. completion 26 August 2013
🇦🇷 AR🇦🇺 AU🇨🇦 CA🇫🇷 FR🇩🇪 DE🇬🇷 GR🇮🇹 IT🇳🇱 NL +6 more

Who might be able to join this trial: - You have been diagnosed with skin melanoma (not eye or mouth/nose melanoma) that has either spread to nearby areas and cannot be removed by surgery (Stage IIIC), or has spread to other parts of the body (Stage IV) - Your melanoma has tested positive for a specific gene change cal...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02211131 · Amgen Phase 2 · 9 countries Completed
Completed Phase 2 Est. completion 30 April 2019
🇦🇺 AU🇧🇷 BR🇫🇷 FR🇬🇷 GR🇵🇱 PL🇷🇺 RU🇪🇸 ES🇨🇭 CH +1 more

**Who might be able to join this trial:** - You have been diagnosed with advanced melanoma (stage IIIB, IIIC, or IVM1a) that doctors believe can be fully removed by surgery. - Any previous cancer treatments (such as chemotherapy, radiation, or other therapies) for your melanoma were finished at least 3 months before jo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02308020 · Eli Lilly and Company Phase 2 · 9 countries Completed
Completed Phase 2 Est. completion 8 November 2018
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇫🇷 FR🇮🇱 IL🇮🇹 IT🇪🇸 ES +1 more

**Who might be able to join this trial:** - You have cancer that has spread to the brain (brain metastases) from hormone receptor positive breast cancer, non-small cell lung cancer (NSCLC), or melanoma. - If joining Part A, you have HER2-positive breast cancer; if joining Part B, you have HER2-negative breast cancer....

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03484923 · Novartis Pharmaceuticals Phase 2 · 10 countries Completed
Completed Phase 2 Est. completion 30 December 2022
🇦🇺 AU🇨🇦 CA🇫🇷 FR🇩🇪 DE🇮🇹 IT🇳🇱 NL🇪🇸 ES🇨🇭 CH +2 more

**Who might be able to join this trial:** - You have been diagnosed with melanoma (a type of skin cancer) that has spread or cannot be removed by surgery, and it has been confirmed by a tissue sample (biopsy). - Your melanoma is classified as an advanced stage (stage IIIB, IIIC, IIID, or IV) using a standard medical s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03815058 · Genentech, Inc. Phase 2 · 6 countries Completed
Completed Phase 2 Est. completion 21 January 2025
🇦🇺 AU🇧🇪 BE🇩🇪 DE🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with melanoma (a type of skin cancer) that has spread to other parts of the body, or cannot be surgically removed, and it started in the skin, hands/feet, or mucous membranes (such as the mouth or nose lining) - Your general health and ability to carry...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04526899 · BioNTech SE Phase 2 · 7 countries Completed
Completed Phase 2 Est. completion 25 January 2024
🇦🇺 AU🇩🇪 DE🇮🇹 IT🇵🇱 PL🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - People who have signed a written consent form before any screening procedures take place - People aged 18 or older at the time of signing the consent form - People who are willing and able to attend scheduled visits, follow the treatment plan, and complete required tests - P...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02402244 · Children's Oncology Group Not Applicable · 6 countries Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇦🇺 AU🇨🇦 CA🇳🇿 NZ Puerto Rico🇸🇦 SA🇺🇸 US

**Who might be able to join this trial:** - People who are 25 years old or younger at the time of their original diagnosis (in some cases, older ages may be accepted if the person is being considered for a specific related treatment study — confirm with trial site) - People who are enrolled within 6 months of first be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT02821013 · Canadian Cancer Trials Group Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 31 December 2027
🇦🇺 AU🇨🇦 CA

**Who might be able to join this trial:** - You are at least 18 years old (or the minimum age stated on the medication's official guidelines). - You have been diagnosed with melanoma that has either spread to other parts of the body or cannot be removed by surgery (stage III or stage IV), confirmed by a tissue test (b...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03340129 · Melanoma Institute Australia Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 August 2026
🇦🇺 AU🇳🇴 NO

**Who might be able to join this trial:** - You are 18 years of age or older (male or female) - You have agreed in writing to take part in the study after being fully informed about it - You have been diagnosed with advanced melanoma (skin, nail area, or mucous membrane type, or of unknown origin) that cannot be surgi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03860883 · Melanoma and Skin Cancer Trials Limited Not Applicable · 10 countries Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇦🇺 AU🇨🇦 CA🇮🇪 IE🇮🇹 IT🇳🇱 NL🇳🇿 NZ🇸🇮 SI🇸🇪 SE +2 more

**Who might be able to join this trial:** - People who have been diagnosed with Stage II invasive skin melanoma of a specific thickness and ulceration status, confirmed by biopsy and laboratory analysis. - People whose melanoma is on the skin (including the head, neck, trunk, arms, legs, scalp, palms, or soles of the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT03947385 · IDEAYA Biosciences Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 29 January 2027
🇦🇺 AU🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older and able to sign a consent form agreeing to take part - You have been diagnosed with uveal melanoma (a type of eye cancer) that has spread to other parts of the body, confirmed by a tissue or cell sample test - Your cancer may be newly diagnos...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04370587 · ImmVira Pharma Co. Ltd Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 22 September 2026
🇦🇺 AU🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - Your cancer has continued to grow or spread after standard treatments, or your doctor believes standard treatments are unlikely to help you - Your cancer type fits one of the following groups: any advanced or spreading cancer (Phase 1); adv...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05180942 · Monash University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇦🇺 AU

**Who might be able to join this trial:** - People who are able to give informed consent and are willing to follow all study requirements - People aged 40 years or older - People who have been diagnosed with melanoma (of any stage) through a tissue biopsy, and who are planned to start, have started, or have already co...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT05280314 · IO Biotech Phase 2 · 6 countries Recruiting
Recruiting Phase 2 Est. completion 30 April 2025
🇦🇺 AU🇩🇰 DK🇫🇷 FR🇩🇪 DE🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** **For people with skin melanoma (melanoma-specific criteria):** - People who have been diagnosed with stage III skin melanoma (confirmed by laboratory testing of tissue), where the cancer has spread to nearby lymph nodes and can be surgically removed — this includes people wit...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05549297 · Immunocore Ltd Phase 3 · 12 countries Recruiting
Recruiting Phase 3 Est. completion 1 March 2028
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇫🇷 FR🇩🇪 DE🇮🇹 IT🇵🇱 PL +4 more

**Who might be able to join this trial:** - People who test positive for a specific genetic marker called HLA-A\*02:01 - People who have melanoma (not of the eye) that cannot be removed by surgery and has been classified as Stage III or Stage IV - People who are able to provide either a stored tumor tissue sample or a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05570227 · Peter MacCallum Cancer Centre, Australia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇦🇺 AU

**Who might be able to join this trial:** - People who have given written consent to participate - People aged 18 years or older at the time of giving written consent - People who have a known melanoma lesion that a doctor has determined needs to be surgically removed or biopsied - People who are willing and able to fo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT05727904 · Iovance Biotherapeutics, Inc. Phase 3 · 16 countries Recruiting
Recruiting Phase 3 Est. completion 1 March 2028
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇫🇮 FI🇫🇷 FR🇩🇪 DE🇮🇱 IL🇮🇹 IT +8 more

**Who might be able to join this trial:** - You have been diagnosed with advanced melanoma (Stage IIIC, IIID, or IV) that cannot be fully removed by surgery or has spread to other parts of the body, confirmed by a lab test on a tissue sample. - Your doctor has assessed that you are generally well enough to carry out d...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06007690 · Aura Biosciences Phase 3 · 14 countries Recruiting
Recruiting Phase 3 Est. completion 15 November 2027
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇨🇿 CZ🇫🇷 FR🇩🇪 DE🇮🇱 IL +6 more

Who might be able to join this trial: - People who have been clinically diagnosed with a primary indeterminate lesion or small choroidal melanoma (a type of eye tumour) (confirm with trial site) - People whose imaging results show no signs that the condition has spread to other parts of the body - People who have not p...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06022029 · OncoNano Medicine, Inc. Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 30 April 2026
🇦🇺 AU🇺🇸 US

**Who might be able to join this trial:** - People who are able to understand the study and are willing to sign a written consent form before any study procedures begin - People aged 18 years or older - People who have a confirmed solid tumour or lymphoma that is advanced, cannot be surgically removed, or has come bac...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06060613 · Obsidian Therapeutics, Inc. Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 30 June 2029
🇦🇺 AU🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older at the time of signing the consent form - People who have a confirmed diagnosis of advanced or metastatic melanoma, or metastatic non-small cell lung cancer (NSCLC) that has returned or stopped responding to treatment - People with melanoma...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06112314 · Immunocore Ltd Phase 3 · 26 countries Recruiting
Recruiting Phase 3 Est. completion 16 October 2027
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇿 CZ +18 more

**Who might be able to join this trial:** - People who test positive for a specific genetic marker called HLA-A\*02:01 - People who have been diagnosed with Stage IV melanoma, or Stage III melanoma that cannot be removed by surgery, confirmed through a tissue biopsy - People who can provide a stored or fresh tumor tis...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06163820 · Melanoma and Skin Cancer Trials Limited Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 January 2026
🇦🇺 AU

**Who might be able to join this trial:** - People who have been diagnosed with melanoma that has spread (confirmed by tissue or cell testing), with tumours in the brain confirmed by imaging. - People whose brain tumours are currently causing symptoms, or who need steroid medication to manage symptoms caused by the br...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06249048 · Strand Therapeutics Inc. Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 May 2027
🇦🇺 AU🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older at the time of screening. - People who are mentally able to understand and sign a consent form. - People with a good general level of functioning — able to carry out normal daily activities with, at most, mild limitations (confirmed using a standard m...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06305962 · Radiopharm Theranostics, Ltd Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 December 2027
🇦🇺 AU

**Who might be able to join this trial:** - People who are 18 years of age or older. - People who have been diagnosed with one of the following cancers that has come back or stopped responding to treatment, and has spread or cannot be removed by surgery: non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
🇦🇺 NCT06326411 · Nested Therapeutics, Inc Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 1 November 2028
🇦🇺 AU🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older (or the legal age of consent in the country where the trial is taking place) - People who have a confirmed advanced or metastatic solid tumour (cancer that has spread or cannot be surgically removed) for which standard treatments do no...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06536257 · Melanoma Institute Australia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇦🇺 AU

**MELANOMA** Who might be able to join this trial: - People who have signed a written agreement to take part and allow their tumour tissue, blood, stool samples, and standard medical information to be used for research - People who have been confirmed by laboratory testing to have melanoma (including skin, mucosal, ac...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT06585410 · Regeneron Pharmaceuticals Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 3 May 2030
🇦🇺 AU🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of skin cancer called invasive cutaneous squamous cell carcinoma (CSCC), confirmed by a laboratory test on a tissue sample. - People whose skin cancer tumour measures at least 1 cm but no more than 2 cm across, and is locat...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06697301 · Eikon Therapeutics Phase 3 · 24 countries Recruiting
Recruiting Phase 3 Est. completion 1 December 2035
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇨🇿 CZ🇩🇰 DK🇫🇮 FI🇫🇷 FR +16 more

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of signing the consent form. - People who are expected to live for at least 3 months. - People who have been diagnosed (confirmed by tissue or cell testing) with Stage 3 (unable to be surgically removed) or Stage 4 melanoma...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06767306 · Melanoma Institute Australia Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 April 2033
🇦🇺 AU🇨🇦 CA

**Who might be able to join this trial:** - You are 18 years of age or older (male or female) - You are willing to sign a consent form agreeing to take part - Your doctors expect you to live for more than 6 months - You have been newly diagnosed with advanced (Stage IV) melanoma that started in the skin, on the hands...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06940739 · Iovance Biotherapeutics, Inc. Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 June 2032
🇦🇺 AU🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of signing the consent form - People who have melanoma that cannot be surgically removed or has spread to other parts of the body - People who have melanoma (not originating in the eye/uvea) where the disease continued to g...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06961006 · Merck Sharp & Dohme LLC Phase 2 · 12 countries Recruiting
Recruiting Phase 2 Est. completion 22 July 2028
🇦🇺 AU🇨🇦 CA🇫🇷 FR🇩🇪 DE🇬🇷 GR🇮🇱 IL🇮🇹 IT🇳🇿 NZ +4 more

**Who might be able to join this trial:** - People who have been diagnosed with Stage III or IV skin melanoma (confirmed by tissue testing) that cannot be surgically removed. - People who have not previously received treatment for melanoma, or who received earlier preventive treatment (before or after surgery) with ce...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06999980 · Melanoma Institute Australia Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2028
🇦🇺 AU

**Who might be able to join this trial:** **Criteria that apply to all groups:** - Adults aged 18 or older who are willing and able to provide written consent to participate. - People whose cancer can be detected through physical examination, standard imaging scans, or PET scans. - People whose cancer can be completel...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07015190 · IDEAYA Biosciences Phase 3 · 21 countries Recruiting
Recruiting Phase 3 Est. completion 1 October 2030
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇨🇿 CZ🇩🇰 DK🇪🇪 EE🇫🇷 FR +13 more

Who might be able to join this trial: - People who have been diagnosed with uveal melanoma (a type of eye cancer) that has not spread to other parts of the body. - People who are willing and able to give written consent before the trial begins, and who are able to follow all study requirements in the opinion of the doc...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07049276 · Melanoma Institute Australia Not Applicable · 6 countries Recruiting
Recruiting Not Applicable Est. completion 1 August 2030
🇦🇺 AU🇨🇦 CA🇮🇱 IL🇮🇹 IT🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older at the time of giving consent - People who are willing and able to give written consent to take part - People who have been confirmed by lab testing (from a tissue or cell sample) to have melanoma of the skin or from an unknown starting point, at a st...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT07063875 · St Vincent's Hospital, Sydney Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇦🇺 AU

Who might be able to join this trial: - People who have been diagnosed with uveal melanoma (a type of eye cancer) that has spread to other parts of the body or cannot be surgically removed, confirmed through a tissue or cell sample. - People who carry a specific genetic marker called HLA-A\*02:01 (a blood test can chec...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07076550 · Alpha-9 Oncology USA Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 January 2028
🇦🇺 AU

**Who might be able to join this trial:** - You are able to read, understand, and sign a consent form agreeing to take part in the study - A special scan (PET scan) using a specific tracer has shown uptake in at least one measurable area of your cancer - Your melanoma has been confirmed by a lab test and cannot be sur...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07086105 · Adze Biotechnology Australia Pty Ltd Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 October 2027
🇦🇺 AU

**Who might be able to join this trial:** - People aged 18 years or older at the time of screening - People who have been diagnosed with advanced or spreading melanoma (Stage IIIB to Stage IV) that has been confirmed by laboratory tissue testing and cannot be surgically removed - People whose melanoma has not responde...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07138222 · Peter MacCallum Cancer Centre, Australia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇦🇺 AU

**Who might be able to join this trial:** - People who have agreed to take part by signing the official consent form for this study - People who have been diagnosed with melanoma at Stage II, III, or IV, whether it is a new diagnosis or the cancer has come back - People whose doctors expect them to live for at least o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT07339176 · Onchilles Pharma Inc Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2028
🇦🇺 AU

Who might be able to join this trial: - People who are 18 years of age or older (or have reached the legal age of consent where the trial is being run). - People who are able to give written consent and are willing and able to attend study visits and follow the study procedures. - People who have an advanced solid tumo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07421739 · Aura Biosciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 August 2028
🇦🇺 AU

Who might be able to join this trial: - People who have already enrolled in a separate Aura-sponsored clinical trial called AU-011-301. - People who have access to a connected device, such as a smartphone, laptop, or tablet. Who may not be able to join: - There are no listed exclusion criteria for this trial. Importa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT01519323 · Hoffmann-La Roche Phase 1 · 10 countries Terminated
Terminated Phase 1 Est. completion 1 December 2015
🇦🇺 AU🇫🇷 FR🇩🇪 DE🇮🇱 IL🇮🇹 IT🇵🇱 PL🇸🇰 SK🇪🇸 ES +2 more

Who might be able to join this trial: - You are between 12 and 17 years old (inclusive) - You have been diagnosed with advanced melanoma (skin cancer) that cannot be removed by surgery, at a serious stage (Stage IIIC or Stage IV) - Your cancer has tested positive for a specific gene change called a BRAF V600 mutation,...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02014116 · Eli Lilly and Company Phase 1 · 4 countries Terminated
Terminated Phase 1 Est. completion 7 April 2017
🇦🇺 AU🇫🇷 FR🇪🇸 ES🇺🇸 US

Who might be able to join this trial: - You have advanced or metastatic cancer (cancer that has spread or is in a late stage) - Other treatments you have tried have not worked to cure your cancer - Your type of cancer does not have a proven effective treatment available - Your cancer can be accessed for a small tissue...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02967692 · Novartis Pharmaceuticals Phase 3 · 29 countries Terminated
Terminated Phase 3 Est. completion 11 August 2020
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇱 CL +21 more

**Who might be able to join this trial:** - You have been diagnosed with melanoma (confirmed by biopsy) that has spread or cannot be removed by surgery, and your tumor has a specific gene change called a BRAF V600 mutation - Your cancer can be measured on a scan (according to standard medical guidelines) - You are gen...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05002569 · Bristol-Myers Squibb Phase 3 · 25 countries Terminated
Terminated Phase 3 Est. completion 16 December 2024
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇱 CL🇨🇳 CN +17 more

**Who might be able to join this trial:** - You have been diagnosed with Stage 3A (with more than 1mm of cancer in the lymph node), 3B, 3C, 3D, or Stage 4 melanoma, confirmed by a tissue biopsy. - Your melanoma has been completely removed by surgery, with no cancer cells found at the edges of the removed tissue. - Your...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07005297 · National Cancer Institute (NCI) Not Applicable · 1 country Not Yet Recruiting
Not Yet Recruiting Not Applicable Est. completion 1 January 2035
🇺🇸 US

**Who might be able to join this trial:** - People of any age (including newborns) with a personal or family history of an unusual type, pattern, or number of cancers or tumors - People with a personal or family history of conditions that may increase cancer risk, such as certain inherited syndromes, birth defects, ch...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00001823 · National Cancer Institute (NCI) Not Applicable · 1 country Recruiting
Recruiting Not Applicable
🇺🇸 US

**Who might be able to join this trial:** - You must be 18 years old or older. - You have either been diagnosed with cancer (confirmed by a tissue sample/biopsy) or doctors suspect you may have cancer. - You are able to understand the study information and are willing to sign a consent form agreeing to take part. - You...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00040352 · National Cancer Institute (NCI) Not Applicable · 1 country Recruiting
Recruiting Not Applicable
🇺🇸 US

Who might be able to join this trial: - People aged 4 weeks or older, of any sex, race, or ethnicity, who have a personal history of melanoma (a type of skin cancer) that is unusual in its type, pattern, or number of occurrences, diagnosed at any age - People with known or suspected factors that may increase their risk...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01205815 · Vanderbilt-Ingram Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with melanoma (a type of skin cancer), confirmed through a lab test or tissue sample - You are scheduled to have a test or procedure that may produce leftover tissue that could be stored for future research, OR you have already had such a procedure but hav...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01438658 · Hadassah Medical Organization Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2040
🇮🇱 IL

Who might be able to join this trial: - People who have been diagnosed with uveal melanoma (a type of eye cancer that starts in the middle layer of the eye) Who may not be able to join: - People who do not wish to take part in the study Important: Always verify eligibility with the trial site directly before applying...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01638676 · University of Louisville Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2025
🇺🇸 US

Who might be able to join this trial: - You must be 18 years of age or older - You must have been diagnosed with a specific type of melanoma (skin cancer) confirmed by a biopsy, with a gene mutation called BRAFV600E, and the cancer must be at an advanced stage (Stage IIIC or Stage IV) - You must be well enough to carry...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01772771 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2032
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with cancer (confirmed by a lab test, scan, or cell sample), or are suspected to have glioma (a type of brain tumor), sarcoma (a type of soft tissue or bone cancer), melanoma (skin cancer), or a blood cancer. - You have a non-cancerous (benign) tumor,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01776905 · University of Arkansas Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇺🇸 US

Who might be able to join this trial: - People aged between 18 and 80 years old - People who have been diagnosed with melanoma, confirmed through a tissue sample (biopsy) - People who have signed a consent form that has been approved by the University of Arkansas for Medical Sciences review board - People who are able...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01898039 · Hadassah Medical Organization Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2027
🇮🇱 IL

**Who might be able to join this trial:** - You must carry at least one of certain specific genetic tissue markers (called HLA types: A2, A24, A33, B35, B49, or CW04/12) — the trial team will test for these (confirm with trial site). - You have been diagnosed with skin melanoma that is at a certain stage of seriousnes...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02280889 · University Children's Hospital, Zurich Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2031
🇨🇭 CH

Who might be able to join this trial: - Children who have a congenital melanocytic nevus (a type of birthmark that is dark and present from birth) that is at least 2 cm² in size and is already planned to be surgically removed - Children aged between 9 months and 16 years Who may not be able to join: - Children who hav...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02332668 · Merck Sharp & Dohme LLC Phase 2 · 10 countries Recruiting
Recruiting Phase 2 Est. completion 2 February 2028
🇧🇷 BR🇫🇷 FR🇩🇪 DE🇮🇱 IL🇮🇹 IT🇵🇹 PT🇰🇷 KR🇸🇪 SE +2 more

Who might be able to join this trial: - Children and young people aged between 6 months and under 18 years old at the time consent is signed - People with a confirmed diagnosis of an advanced or spreading solid tumour or lymphoma that cannot be cured and has not responded to standard treatments, or where no standard tr...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02621021 · National Cancer Institute (NCI) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 16 June 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have measurable metastatic melanoma (melanoma that has spread) with at least one tumour that can be surgically removed to grow specialised immune cells in the lab. - People whose melanoma diagnosis has been confirmed by the National Cancer Institute's (NCI) pathol...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02775643 · St. Jude Children's Research Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2031
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with, or are suspected of having, a melanocytic lesion (a type of skin growth involving pigment-producing cells), including types such as conventional melanoma, Spitzoid melanoma or atypical Spitz tumor, congenital melanoma, melanoma arising from a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02828202 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇫🇷 FR

**Who might be able to join this trial:** **Group 1 – People with melanoma that can be surgically removed (Resectable Stage II or III):** - People diagnosed with stage IIA, IIB, IIC, or III melanoma that can be surgically removed, confirmed by a tissue test (biopsy) - People who have not yet received any systemic (who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02870244 · Loyola University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2028
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with metastatic melanoma (melanoma that has spread) that can be measured or seen either by physical examination or by imaging scans. - People who are 18 years of age or older. - People who have signed and dated an approved consent form agreeing to t...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03054584 · University of California, Davis Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2028
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 years or older - People who have melanocytic nevi (moles or pigmented spots on the skin made up of melanocyte cells) Who may not be able to join: - People under the age of 18 - People who do not have melanocytic nevi (moles or pigmented spots on the skin made up o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03315468 · Nantes University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2030
🇫🇷 FR

Who might be able to join this trial: - People who have been diagnosed with melanoma, at any stage of the disease - People who have agreed to take part in the trial Who may not be able to join: - People who are currently under the legal protection of a court (such as those under guardianship or a similar legal arrange...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03563729 · Inge Marie Svane Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2024
🇩🇰 DK

**Who might be able to join this trial:** - People who have been diagnosed with metastatic melanoma (skin cancer that has spread) that has also spread to the brain, confirmed by scans and tissue testing - People whose brain metastases require regular steroid medication (above certain doses) to manage symptoms - People...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03567889 · Philogen S.p.A. Phase 3 · 3 countries Recruiting
Recruiting Phase 3 Est. completion 1 December 2027
🇪🇸 ES🇨🇭 CH🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with stage IIIB, IIIC, or IIID melanoma (using the AJCC 8th edition staging system) that has spread to nearby areas but can be completely removed by surgery. - People who have at least one melanoma lesion in the skin, tissue just under the skin...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03646617 · Abramson Cancer Center at Penn Medicine Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with melanoma that has spread to other parts of your body, confirmed by a tissue sample (biopsy). - You have at least two measurable tumors that can be tracked using standard imaging measurements. - One of your tumors (the main one being treated) meas...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03685890 · Vastra Gotaland Region Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇳🇱 NL🇸🇪 SE

**Who might be able to join this trial:** - People aged 18 or older, of any gender - People who have given written consent before any trial procedures begin - People who have been diagnosed through laboratory testing with melanoma that has spread within the skin or nearby tissue (called "in-transit metastases"), with...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03702309 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 6 July 2026
🇨🇦 CA

**Who might be able to join this trial:** - You have been diagnosed with a solid tumor or a blood cancer, confirmed by a tissue sample (biopsy), OR you have been identified as being at high risk of developing cancer (for example, because you carry a gene linked to cancer, or because of your hormone levels or family his...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03809585 · Oregon Health and Science University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: **If you have an iris tumor:** - You have been diagnosed with a tumor on the colored part of your eye (iris), which may be pigmented (dark) or non-pigmented (light-colored) **If you are joining as a healthy volunteer:** - Your eyes have no known defects, damage, or growths on the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03819296 · M.D. Anderson Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 October 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with melanoma, non-small cell lung cancer, or a urinary/reproductive system cancer (any stage), or any type of cancer depending on which part of the study you join - You are currently being treated with a type of immunotherapy called an immune checkpo...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03829254 · NuCana plc Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2026
🇬🇧 GB

**Who might be able to join this trial:** - People who have signed and provided written consent to participate. - People with an advanced solid tumour (confirmed by tissue testing) that can be measured or detected on scans or fluid samples — this applies to most parts of the trial except the melanoma combination group...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03842943 · University of Louisville Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older, of any race or sex, and have been diagnosed with skin melanoma confirmed by a medical test (such as a biopsy) - You are generally able to carry out daily activities with little to no limitation (your doctor will assess this using a standard...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03888950 · Centre Hospitalier Universitaire de Nice Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 24 November 2022
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with advanced melanoma (a type of skin cancer) that has been confirmed by a lab test, and your melanoma started on the skin or from an unknown location - Your doctor has recommended you receive an immune therapy treat...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03941756 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 years or older. - People who are willing to take part in the study. - People who are able to understand and sign a consent form. - People diagnosed with inflammatory breast cancer, or locally advanced non-inflammatory breast cancer, who are having lymph nodes remov...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04068155 · Alpha Tau Medical LTD. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇫🇷 FR

**Who might be able to join this trial:** - You have been diagnosed with a skin cancer that has been confirmed by a tissue test (biopsy), either newly diagnosed or returned after previous treatment, and it is one of these types: squamous cell carcinoma (SCC), basal cell carcinoma (BCC), lentigo maligna melanoma, or ca...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04126876 · A.J.M. van den Eertwegh Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2021
🇳🇱 NL

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed with primary skin melanoma (confirmed by laboratory testing of tissue) where the tumour measures more than 2.0 mm in depth - People who are already scheduled to have surgery to remove more tissue around the original t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04318717 · Washington University School of Medicine Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 July 2030
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with mucosal melanoma (a type of melanoma affecting inner surfaces of the body) that has been confirmed by lab testing and surgically removed. - You have not had radiation therapy in the area being studied. - You are at least 16 years old. - You are g...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04331093 · Di Wu Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old. - You have been diagnosed with acral melanoma (a type of melanoma found on palms, soles, or under nails) at stage III or IV that can be surgically removed, and you have at least one measurable area of disease that has not already been tre...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04386967 · Binhui Biopharmaceutical Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 13 March 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with an advanced (stage III or IV) cancer that cannot be treated with surgery, confirmed by lab tests — including breast cancer, stomach/intestinal cancer, liver cancer, cervical cancer, melanoma, head and neck cancers, or soft tissue sarcomas (melano...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04389281 · Immunolight, LLC Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2028
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older who are able to give written agreement to take part in the study - People who are generally well enough to carry out light activity or desk work (a doctor will assess this using a standard scale) - People with an advanced solid tumour cancer that has...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04424719 · Institut Curie Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 7 July 2037
🇫🇷 FR

Who might be able to join this trial: - People aged 18 years or older - People diagnosed with uveal melanoma (a type of eye cancer) that carries a high risk of spreading, defined by either the size or stage of the tumour (T2b, T2c, T2d, or T3 and above), or by specific abnormalities found on chromosomes 3 or 8 through...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04474301 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have already signed consent for a related study (PA15-0336) - People who have an active email address and can be reached through the MyChart patient messaging system - People who are confirmed to be living, based on records held by the cancer registry **Who may no...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04493723 · The Christie NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2034
🇬🇧 GB

**Who might be able to join this trial:** - People aged 16 years or older - People who are willing and able to give written consent to take part - People who have been diagnosed with locally advanced or metastatic melanoma (also called stage III or stage IV melanoma) - People who have a tumour that a doctor can safely...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04511013 · SWOG Cancer Research Network Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with melanoma (confirmed by lab testing) that has spread to the brain, from any primary site such as the skin, except uveal (eye) melanoma. - People whose melanoma has a specific gene change called a BRAF-V600 mutation, confirmed by an approved labo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04548817 · Memorial Sloan Kettering Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 3 September 2027
🇺🇸 US

**Who might be able to join this trial:** - People who were born with a large, dark-coloured patch of skin (which can appear anywhere on the body) - People whose skin condition may include smaller additional patches nearby (called satellite lesions) - People whose skin condition may be associated with excessive hair g...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04567706 · Ohio State University Comprehensive Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with malignant melanoma, or who have had melanoma in the past - People who are healthy donors (no melanoma diagnosis required) - People at any stage of malignant melanoma are included - People who are able to provide informed consent (agreement to t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04572451 · Yana Najjar Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 17 May 2024
🇺🇸 US

**Who might be able to join this trial:** **Safety Cohort (for people with various solid tumours):** - People who have advanced, spread, or inoperable solid tumours that have continued to grow despite standard treatments (people with melanoma and kidney cancer will make up roughly 30% of this group) - People who have...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04576429 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2031
🇫🇷 FR

**Who might be able to join this trial:** - People aged 18 years or older - People who have had stage III or IV melanoma fully removed by surgery and are being treated with an immunotherapy drug (such as pembrolizumab, nivolumab, or a similar type of drug called an immune checkpoint inhibitor) as a follow-up treatment...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04594187 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are planned to receive immunotherapy after surgery - People who have no signs of cancer that has spread to distant parts of the body, based on physical examination and imaging scans - People who had no signs of cancer in their lymph nodes before a sentinel lymph n...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04598009 · University of California, San Francisco Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 May 2027
🇺🇸 US

**Who might be able to join this trial:** - People whose general health and ability to carry out daily activities meets a minimum level of functioning, assessed using a standard scale (confirm with trial site) - People whose melanoma has been confirmed through laboratory testing of tissue or cell samples - People with...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04605146 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 5 November 2028
🇫🇷 FR

**Who might be able to join this trial:** - People who are over 18 years old - People who have been diagnosed with melanoma, lung cancer, or kidney cancer - People who are starting a treatment combining two immunotherapy drugs called nivolumab and ipilimumab (people who have had immunotherapy treatment in the past may...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04616443 · Binhui Biopharmaceutical Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 November 2025
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with stage III or stage IV cancer (confirmed by a tissue test) that cannot be treated with surgery. - People whose cancer has not responded to standard treatments, including PD-1 immunotherapy on its own, or whose cancer came back or spread within 6 months o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04658303 · Yana Najjar Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2029
🇺🇸 US

**Who might be able to join this trial:** - People who are willing and able to sign a written consent form for the trial - People who are 18 years of age or older at the time of signing the consent form - People who have a confirmed diagnosis of melanoma with at least two in-transit lesions (small tumours that have sp...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04697576 · Carlo Contreras Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 September 2027
🇺🇸 US

**Who might be able to join this trial:** - People of any gender, aged 18 to 99 years - People who have been diagnosed with skin (cutaneous) melanoma, confirmed by a tissue sample examined in a lab — either early-to-mid stage (Stage I–III, Cohort 1) or advanced stage (Stage IV, Cohort 2) - People who have at least one...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04729543 · Erasmus Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 20 December 2024
🇳🇱 NL

**Who might be able to join this trial:** - You are 18 years of age or older - You have one of the following cancers: melanoma of the skin or mucous membranes (that cannot be surgically removed or has spread) and no standard treatments are left; melanoma of the eye (uveal melanoma) that has spread and has gotten worse...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04741997 · H. Lee Moffitt Cancer Center and Research Institute Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 22 July 2026
🇺🇸 US

Who might be able to join this trial: - You must be 18 years old or older when you sign the consent form - You must have been diagnosed with melanoma (confirmed by a tissue sample), from any location on the body or of unknown origin - Your melanoma must have a specific gene change called a BRAFV600 mutation, and must b...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT04771520 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older (or adolescents aged 12 and older, with signed assent and parental consent, following institutional guidelines) who agree in writing to take part in the study. - People in Cohorts 1 and 2 who have an advanced or metastatic solid tumour (including but...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04778449 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with melanoma, a related skin condition, or a precursor skin lesion (an early skin change that could develop into melanoma) - You are able to read and understand English - You are willing to fill out a survey, either online or on paper Who may not be able...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04787042 · Simcha IL-18, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2025
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender - People who are willing and able to provide written consent to participate, along with any other authorisations required by local law - People who have a relatively good level of general physical functioning (rated 0 or 1 on a standard...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04793737 · Karolinska University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇸🇪 SE

**Who might be able to join this trial:** - People aged 18 or older - People whose general health and activity level meets a specific performance standard (rated 0 or 1 on a scale used by doctors to measure how much a condition affects daily activities — confirm with trial site) - People who have signed and dated a co...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04844528 · University of Utah Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2026
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older. - People who have been diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL), confirmed using standard 2018 diagnostic guidelines. - People who have had at least one non-melanoma skin cancer diagnosed within the last 5...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04855435 · MonTa Biosciences ApS Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 1 March 2027
🇩🇰 DK🇪🇸 ES

**Who might be able to join this trial:** **General requirements (all participants):** - Adults aged 18 or older - People who are generally well enough to carry out light activity and care for themselves (a doctor will assess this using a standard scale) - People whose doctors estimate they have a life expectancy of a...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04899908 · Brigham and Women's Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have a solid cancer (confirmed by biopsy) that has spread to the brain, with at least one brain tumour measuring 5mm or larger on a scan. - The brain tumour(s) must fall into at least one of these categories: melanoma that has continued growing in the brain despit...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04903119 · Rina Plattner Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2028
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with melanoma that has spread to other parts of the body or cannot be surgically removed, confirmed by a tissue biopsy. - You have a specific gene change in your tumor called a "BRAF V600 mutation," confirmed by an approved lab test. - Your melanoma h...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04986748 · National Cancer Centre, Singapore Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2028
🇸🇬 SG

Who might be able to join this trial: - You have been diagnosed with sarcoma or melanoma (a type of cancer). - You have at least one tumour that can be safely biopsied (a small sample taken) or surgically removed. - You or your legal representative are able and willing to sign a consent form agreeing to take part. - Yo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04996823 · H. Lee Moffitt Cancer Center and Research Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 20 August 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with advanced or inoperable melanoma (not including uveal melanoma, which is a type that starts in the eye) - People who are reasonably active and able to care for themselves, as measured by a standard health scoring scale (ECOG score of 2 or below)...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05026983 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 2 February 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are able to give written consent to participate in the study - People who are 18 years of age or older at the time of giving consent - People who have been diagnosed with melanoma confirmed through laboratory tissue testing - People whose melanoma tumour has been...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05029791 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 November 2031
🇫🇷 FR

Who might be able to join this trial: - Adults aged 18 or older - Female participants must agree to use 2 forms of contraception during the study; male participants must use 1 form of contraception if their partner could become pregnant, during the study and for at least 5 months after the last treatment - People with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05033678 · Region Skane Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2029
🇸🇪 SE

Who might be able to join this trial: - People who have a skin lesion that a doctor has examined during an in-person visit - People whose doctor has decided to send their case for a teledermoscopy referral (a remote specialist review of skin images) Who may not be able to join: - People who are unable or unwilling to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05037825 · VastBiome Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 14 September 2023
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older - People who tested negative for COVID-19 symptoms at the time of joining, following the hospital's guidelines during the pandemic - People diagnosed with stage I–IV of one of these cancers: non-small cell lung cancer (NSCLC), melanoma (MM), triple-neg...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05077137 · Duke University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with advanced melanoma that has spread to other parts of the body, confirmed through a tissue sample (biopsy) - You are 18 years of age or older at the time of signing the consent form - Your doctor has planned for you to receive a type of immunotherap...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05098184 · Shanghai Juncell Therapeutics Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 25 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years - People who have been diagnosed with primary, relapsed, or metastatic melanoma confirmed by tissue testing - People whose life expectancy is more than 3 months - People who have a reasonable level of general physical functioning (as assessed by a...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT05098210 · Fred Hutchinson Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 November 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older (any gender) - People whose overall health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scale (ECOG score of 0, 1, or 2) - People who have at least one tumour or group of tumours large e...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05136196 · National Cancer Institute (NCI) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been confirmed by biopsy to have stage III or IV melanoma (not uveal/eye melanoma) that cannot be surgically removed, has come back, or has spread to other parts of the body. - People who have been confirmed by biopsy to have squamous cell cancer of the head...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05155033 · National Cancer Institute (NCI) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2031
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with one of the following cancers, confirmed by a lab test: (1) melanoma that has spread or cannot be surgically removed and has stopped responding to a type of immunotherapy called anti-PD-1 therapy; (2) kidney cancer (clear cell type) that has sprea...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05229614 · CNAO National Center of Oncological Hadrontherapy Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 August 2025
🇩🇪 DE🇮🇹 IT

**Who might be able to join this trial:** - You are willing and able to sign a consent form agreeing to take part in the study - You have been diagnosed with a cancer that has been confirmed by a tissue sample (biopsy), and you are currently being treated with a single approved immunotherapy drug that works by blockin...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05231655 · Sheffield Teaching Hospitals NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2026
🇬🇧 GB

Who might be able to join this trial: - People aged over 16 who have been diagnosed with, or are suspected to have, a solid cancer (a tumour that forms in an organ or tissue, not blood) and who are scheduled to have surgery, a biopsy, a fluid sample taken, or a procedure to remove bladder tumour tissue (TURBT) - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05251389 · The Netherlands Cancer Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2026
🇳🇱 NL

**Who might be able to join this trial:** - People aged 18 years or older - People who have been diagnosed with advanced skin melanoma (stage III or IV) that has been confirmed by a tissue sample and requires treatment with an anti-PD-1 medication (a type of immunotherapy) - For stage IV disease, only people with a sp...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05253872 · Herlev and Gentofte Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2024
🇩🇰 DK

**Who might be able to join this trial:** - You are able to read and understand Danish - You are willing and able to sign a consent form agreeing to take part - You have had surgery to treat an early-stage melanoma (stage IA to IIA) within the last 3 months **Who may not be able to join:** - You have been diagnosed wi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05264974 · University of Florida Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older. - People whose general physical functioning is rated at a level showing they are able to care for themselves, even if unable to carry out strenuous activity (confirm with trial site regarding the specific rating scale used). - People whose blood test...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05307289 · Centre Hospitalier Universitaire de Nice Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 May 2028
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years of age or older (male or female) - You have been diagnosed with advanced melanoma (skin cancer) that either cannot be surgically removed (Stage III) or has spread to other parts of the body (Stage IV), including cases where the original source of the melanoma...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05361174 · Iovance Biotherapeutics, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with Stage IIIC, IIID, or IV melanoma that cannot be removed by surgery or has spread to other parts of the body, or Stage III or IV non-small cell lung cancer (NSCLC). - People with melanoma whose cancer has continued to grow within 12 weeks o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05366478 · Suzhou BlueHorse Therapeutics Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 May 2024
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with stage III or IV melanoma, non-small cell lung cancer, cervical cancer, or other solid tumours (confirmed by tissue testing) where existing treatments have stopped working or no standard treatment is available. - People who have tumour(s) large enough (g...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05373823 · Rutgers, The State University of New Jersey Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with primary skin melanoma (a type of skin cancer) at stages 0 through III - People who had surgery between three months and five years ago to treat their melanoma - People who currently show no signs of cancer - People who have not been doing regul...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05384496 · Memorial Sloan Kettering Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with mucosal melanoma (a type of skin cancer affecting inner body surfaces) that cannot be surgically removed, located in areas such as the head/neck (like the nose, sinuses, or mouth), digestive tract (like the rectum or esophagus), or urinary/reprod...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05423262 · Toray Industries, Inc Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇯🇵 JP

**Who might be able to join this trial:** - People with a confirmed advanced or spreading solid tumour cancer that has stopped responding to standard treatments, cannot tolerate standard treatments, or for whom no standard treatment exists (Part 1); or people with a confirmed advanced or spreading solid tumour who wou...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05428007 · NYU Langone Health Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have signed and dated a written consent form approved by an ethics committee, before any study-related procedures begin. - People who are willing and able to attend scheduled visits, follow the treatment plan, have laboratory tests, tumor biopsies, and meet other...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05446155 · Region Skane Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇸🇪 SE

**Who might be able to join this trial:** - People who are receiving routine dermatology (skin specialist) care at Helsingborg, Lund, or Malmö Hospitals and are scheduled for surgical removal of a suspicious pigmented skin spot that doctors are investigating as a possible melanoma (primary part of the trial) - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05478876 · CNAO National Center of Oncological Hadrontherapy Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇮🇹 IT

**Who might be able to join this trial:** - People who have had a tissue biopsy confirming their diagnosis - People whose cancer has not spread to the skin - People whose cancer has spread to nearby lymph nodes, but only if those lymph nodes are limited to the groin and pelvis area - People between the ages of 20 and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05483400 · University Medical Center Groningen Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2025
🇳🇱 NL

**Who might be able to join this trial:** - People who have one or more tumour lesions from which a tissue sample (biopsy) can be safely taken using standard medical procedures. - People whose cancer can be measured on scans, following standard measurement guidelines (RECIST v1.1). Lesions that have already been treat...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05492682 · Valo Therapeutics Oy Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 30 April 2027
🇩🇪 DE🇮🇹 IT

**Who might be able to join this trial:** - You are 18 years of age or older - You have given written consent to take part in the study - You have been diagnosed with one of the following cancers that cannot be surgically removed or has spread, confirmed by tissue testing: skin melanoma; triple-negative breast cancer...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05498792 · Fox Chase Cancer Center Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 4 March 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with stage III melanoma that has spread to one or more lymph nodes in a way that can be measured on scans, and where a biopsy or surgery is possible - People whose treating doctor has determined they have stage III or stage IV melanoma where ti...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT05502900 · Gustav Stalhammar Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2031
🇸🇪 SE

**Who might be able to join this trial:** - People aged 18 or older - People who have given written consent to take part in the trial - People diagnosed with a melanoma (a type of cancer) starting in a specific part of the eye called the choroid or the ciliary body, confirmed by clinical assessment and/or laboratory e...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05512481 · Peking University Cancer Hospital & Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years, of any gender - People who have been diagnosed with acral melanoma (a type of melanoma found on the hands, feet, or nails) at Stage II or III, confirmed by a tissue biopsy - People who have not yet received any drug-based cancer treatment - People...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05522660 · ETOP IBCSG Partners Foundation Phase 3 · 5 countries Recruiting
Recruiting Phase 3 Est. completion 1 September 2026
🇮🇹 IT🇳🇱 NL🇪🇸 ES🇨🇭 CH🇬🇧 GB

**Who might be able to join this trial:** - People aged 18 or older who have been diagnosed with brain metastases that have not yet been treated (other than surgery) - People whose brain metastases are causing no symptoms, or only mild symptoms that do not require more than a low, stable dose of steroid medication (4...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05527795 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2029
🇫🇷 FR

Who might be able to join this trial: - You have been diagnosed with stage II, III, or IV melanoma (a type of skin cancer) that has been surgically removed - You received surgery and additional immune-boosting treatment (immunotherapy) after surgery, at some point between January 1, 2019 and January 1, 2029 - You are w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05546827 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 July 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have a mucosal tumour (a tumour on the moist lining of a body cavity) that can be seen on a physical exam or imaging scan. - People whose cancer has not spread to distant parts of the body. - People who are already planned to receive a combination immunotherapy tr...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05588453 · Kari Kendra Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 April 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with melanoma (confirmed by tissue testing) that has spread to other parts of the body (stage IV). - People who have at least one brain tumour spot, confirmed by a specific type of brain scan (MRI with contrast dye), that is 10mm or larger and...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05607095 · Memorial Sloan Kettering Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 May 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have a confirmed diagnosis of metastatic uveal melanoma (Cohort 1), regardless of how many previous treatments they have had. - People who have a confirmed diagnosis of unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated lipos...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05620290 · Sunnybrook Health Sciences Centre Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 11 July 2025
🇨🇦 CA

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with melanoma or another type of skin cancer (confirmed by biopsy), including cases where the cancer has spread to other parts of the body - Your skin cancer is classified as Stage I through Stage IV according to stan...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05649683 · Centre Hospitalier Universitaire de Nice Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇫🇷 FR

Who might be able to join this trial: - Adults aged 18 or older - People who have been diagnosed with advanced melanoma - People whose disease can be measured using standard imaging guidelines (known as RECIST 1.1 criteria) - People who have not yet received any treatment for their advanced melanoma (this would be thei...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05652673 · Erasmus Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇳🇱 NL

**Who might be able to join this trial:** - Adults aged 18 or older - People diagnosed with melanoma that cannot be surgically removed (stage III) or that has spread to other parts of the body (metastatic) - People who have received at least one dose of a combination treatment called ipilimumab-nivolumab as their firs...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05655312 · Perspective Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with melanoma that cannot be surgically removed and has either spread to other parts of the body or come back after previous treatment (Stage III or Stage IV) - People whose melanoma continued to grow or spread despite...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05673681 · Fundación Academia Española de Dermatología Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2032
🇪🇸 ES

Who might be able to join this trial: - People who have been diagnosed with invasive primary melanoma that started in the skin (as opposed to other parts of the body), at one of the participating medical centres. Who may not be able to join: - People whose melanoma is "in-situ," meaning it is confined to the outer lay...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05704647 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 July 2028
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older - People whose doctors estimate they have more than 12 weeks to live - People who are willing and able to attend scheduled visits, follow the treatment plan, and complete required tests throughout the study - People who have been diagnosed with malign...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05733728 · Medical University of Vienna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇦🇹 AT

Who might be able to join this trial: - Adults aged 18 to 99 years old - People who have been diagnosed with uveal melanoma (a type of eye cancer that starts in the middle layer of the eye) Who may not be able to join: - People younger than 18 years of age - People whose medical records are incomplete or missing impor...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05779423 · Massachusetts General Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇺🇸 US

**Who might be able to join this trial:** - You are an adult (over 18) with melanoma that cannot be surgically removed, and your cancer has continued to grow or spread after receiving certain immunotherapy treatments (such as pembrolizumab, nivolumab, or ipilimumab) - Your doctor is planning to start you on a combinat...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05789043 · Peking University Cancer Hospital & Institute Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 15 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older, of any sex - People with acral melanoma (a type of melanoma that typically appears on palms, soles, or under nails) that has been confirmed by laboratory testing and has either come back, cannot be fully removed by surgery, or has spread to other part...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05794035 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇫🇷 FR

Who might be able to join this trial: - People aged 70 years or older - People with a performance status rated 0 to 3 on the OMS scale, meaning they are able to carry out at least some daily activities (confirm with trial site) - People who have had a laboratory test confirming a type of skin cancer called invasive squ...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05797415 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2025
🇮🇹 IT

**Who might be able to join this trial:** - You have been diagnosed with Porocarcinoma, Merkel cell carcinoma, or Sebaceous carcinoma (specific rare skin cancers) - You have a type of skin melanoma (from sweat or oil glands) that is relatively thick, has grown to a certain depth, and shows signs of active cell divisio...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05839912 · Craig L Slingluff, Jr Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older at the time of enrolment. - People who are willing and able to follow all study procedures for the full duration of the trial, and who have signed and dated a consent form. - People whose overall health and ability to carry out daily activities falls...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05856565 · Nantes University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 24 July 2028
🇫🇷 FR

**Who might be able to join this trial:** - You are an adult with advanced (stage III or IV) melanoma, or a skin cancer (squamous cell or basal cell carcinoma) that cannot be removed by surgery - For the **retrospective group** (looking back at past treatment): you have already been receiving a specific type of immuno...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05867004 · Institut Claudius Regaud Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 3 July 2025
🇫🇷 FR

Who might be able to join this trial: - You must already be taking part in the TICIMEL clinical trial (a separate study with the reference number NCT03293784) - You must already be taking part in the MELANFα clinical trial (a separate study with the reference number NCT03348891) Who may not be able to join: - There ar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05868707 · Binhui Biopharmaceutical Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 March 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with stage III or stage IV melanoma (confirmed by lab testing) and have already tried at least two standard treatments, such as chemotherapy, immunotherapy, or targeted therapy, without success - You have a good gene...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05877430 · CJ Bioscience, Inc. Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 July 2026
🇰🇷 KR🇺🇸 US

**Who might be able to join this trial:** - People who are willing and able to give informed consent to participate - People who are 18 years of age or older at the time of signing the consent form - People who have been diagnosed with non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), or...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05878964 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 22 July 2025
🇮🇹 IT

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with a solid tumour (a type of cancer that forms a lump or mass), confirmed by laboratory testing of tissue - People who are able to fill in questionnaires throughout the study - People who are willing to sign a consen...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05896839 · National Cancer Institute (NCI) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 January 2027
🇺🇸 US

**Who might be able to join this trial:** - You must be a kidney transplant recipient whose transplanted kidney is currently working and you are not on dialysis - You must be 18 years of age or older - You must have a confirmed diagnosis of one of these skin cancers: melanoma (not of the eye), basal cell carcinoma, Me...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05899465 · University of Aarhus Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 September 2026
🇩🇰 DK

Who might be able to join this trial: - People who have been diagnosed with invasive skin melanoma at a certain level of severity, meaning the tumour is either between 1.0–2.0 mm thick with signs of ulceration (skin breakdown), or more than 2.0 mm thick regardless of ulceration - People who are suitable for surgery, sp...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05909618 · Sheba Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 July 2028
🇮🇱 IL

# Clinical Trial NCT05909618 – Eligibility in Plain Language This trial has **three groups (cohorts)**. Please read the section that may apply to the patient's situation. --- ## COHORT 1 – Melanoma that has spread to the brain (MBM) **Who might be able to join this trial:** - People aged 18 or older - People with a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05940311 · Regina Elena Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2024
🇮🇹 IT

Who might be able to join this trial: - People aged 18 or older - People who have had 2 or fewer prior lines of treatment for their condition (confirm with trial site) - People who are willing to sign a consent form agreeing to take part in the study - People who have been diagnosed with skin melanoma, confirmed by a l...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05955924 · Women's College Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 August 2027
🇨🇦 CA

Who might be able to join this trial: - People who are 18 years of age or older - People who received a kidney, liver, heart, or lung transplant at least two years ago - People who have previously been diagnosed with a type of skin cancer called keratinocyte carcinoma, or a very early form of squamous cell skin cancer,...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05968690 · Sarah Weiss Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 September 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older who are able to understand and sign a consent form - People who have been confirmed through a tissue test (biopsy) to have melanoma that cannot be surgically removed and is classified as stage III or stage IV - People whose doctor has determined they a...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05970497 · Krystal Biotech, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2027
🇺🇸 US

**Who might be able to join this trial:** - People with a life expectancy of more than 12 weeks - People with a good general level of physical functioning (rated 0 or 1 on a standard medical scale, meaning able to carry out normal daily activities with little or no restriction) - People who have at least one area of d...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05983237 · Jun Guo Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with melanoma (a type of skin cancer) that has spread or cannot be removed by surgery, at an advanced stage (stage III or IV) - Your cancer has a specific genetic change known as an HR and/or SF3B1 mutation (a lab test would confirm this) - Your cancer...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06008106 · Shanghai Kechow Pharma, Inc. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 22 September 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older. - People diagnosed with melanoma that cannot be surgically removed (stage III) or has spread to other parts of the body (stage IV), confirmed by a tissue or cell test. - People whose melanoma did not respond to immunotherapy, or who were unable to to...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06066138 · National Cancer Institute (NCI) Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 January 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older who have been diagnosed with a locally advanced or metastatic cancer (confirmed by laboratory testing), where their treating specialist has determined that the immunotherapy drug atezolizumab — alone or combined with other approved drugs — is an appro...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06070012 · Diwakar Davar Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with metastatic uveal melanoma (a type of eye cancer that has spread) confirmed through a laboratory test of tissue or cells, and who have not yet received treatment for it. - People who carry a specific genetic marker called HLA-A\*0201, confi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06081920 · Innovent Biologics (Suzhou) Co. Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 6 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with melanoma that has been confirmed by lab testing, cannot be surgically removed, and has either spread to nearby areas or to other parts of the body (stage III or IV), and your cancer has come back or gotten worse after at least one previous standa...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06090266 · OncoResponse, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older who have signed a consent form before any study procedures begin. - People who have been diagnosed (confirmed by tissue testing) with a carcinoma, sarcoma, or melanoma that has spread or is locally advanced and cannot be treated with curative local th...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06121180 · H. Lee Moffitt Cancer Center and Research Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2030
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older, of any gender. - People with a life expectancy of more than 3 months, in the opinion of the study doctor. - People who are able and willing to sign a consent form (or have a legally authorised representative sign on their behalf). - People who have b...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06154668 · University Hospital, Grenoble Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇫🇷 FR

Who might be able to join this trial: - People who have been diagnosed with melanoma (a type of skin cancer) that has been confirmed through a tissue sample (biopsy), at any stage from I to IV. - People who are able to give their signed agreement to have their past medical data used, or who are willing to agree to thei...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06194929 · University of Utah Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 January 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older at the time of giving consent to participate. - People who are able to provide written consent to participate (if someone cannot write their consent due to an impairment, the trial site may be able to follow local procedures to obtain consent in anoth...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06203249 · Chinese PLA General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2025
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with a muscle and skin condition called dermatomyositis and have tested positive for a specific antibody called anti-MDA5. - People with anti-MDA5-positive dermatomyositis who also have a rapidly progressing form of lung scarring/inflammation (confi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06204991 · Inge Marie Svane Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 March 2027
🇩🇰 DK

**Who might be able to join this trial:** - People who have been diagnosed with melanoma that cannot be surgically removed or has spread to other parts of the body (stage IIIc or stage IV), confirmed by a tissue biopsy. - People whose melanoma has continued to grow or spread after receiving standard immunotherapy trea...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06206707 · University of Aarhus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇩🇰 DK

**Who might be able to join this trial:** - You are 18 years of age or older. - You have been diagnosed with malignant melanoma (skin cancer) and/or kidney cancer, confirmed by a tissue sample test. - You have received a specific type of cancer immunotherapy drug (such as Nivolumab, Pembrolizumab, Cemiplimab, Atezolizu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06209580 · Multitude Therapeutics Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing and able to understand and sign a consent form, and to follow the study schedule and requirements. - People who have been diagnosed with melanoma or another advanced solid tumour, confirmed by tissue testing. - People who have already received at least...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06214156 · Shanghai Pharmaceuticals Holding Co., Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with advanced melanoma - People who have at least one tumour that can be measured on a scan - People whose general health and ability to carry out daily activities is rated as good or mostly independent (ECOG score of 0 or 1) - People whose doc...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06216938 · Yana Najjar Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 31 March 2028
🇺🇸 US

**Who might be able to join this trial:** - You are willing and able to sign a written consent form to take part in the trial. - You are 18 years of age or older at the time of signing the consent form. - You have been diagnosed with a specific advanced stage of melanoma (pT3b, T4a, or T4b) confirmed by a biopsy, with...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06223659 · Ohio State University Comprehensive Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are biologically male or female, aged 18 to 99 years - People who have been diagnosed with a skin cancer (such as cutaneous melanoma, Merkel cell carcinoma, squamous cell carcinoma, or another type of skin cancer) confirmed by a tissue sample, and for whom a doctor...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06229340 · N.N. Petrov National Medical Research Center of Oncology Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2026
🇷🇺 RU

**Who might be able to join this trial:** - People who are able to give informed consent and sign the required study forms - People who are 18 years of age or older - People whose cancer-related physical functioning falls within a certain range, meaning they are either fully active, have some limitations but can care...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06240143 · The Netherlands Cancer Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2029
🇳🇱 NL

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender - People whose general health and ability to carry out daily activities meets a specific fitness standard (called WHO Performance Status 0 or 1 — confirm with trial site) - People with a confirmed diagnosis of skin melanoma that has gro...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06246149 · European Organisation for Research and Treatment of Cancer - EORTC Phase 3 · 9 countries Recruiting
Recruiting Phase 3 Est. completion 1 November 2032
🇧🇪 BE🇫🇷 FR🇩🇪 DE🇳🇱 NL🇵🇱 PL🇪🇸 ES🇸🇪 SE🇬🇧 GB +1 more

**Who might be able to join this trial:** - People diagnosed with uveal melanoma (a type of eye cancer) that has not spread to other parts of the body, and whose cancer is not in the iris part of the eye, and who have already completed surgery or radiotherapy as their main treatment - People whose main treatment was c...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06264180 · Replimune, Inc. Phase 3 · 7 countries Recruiting
Recruiting Phase 3 Est. completion 30 September 2030
🇫🇷 FR🇩🇪 DE🇬🇷 GR🇵🇱 PL🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - People aged 12 or older at the time of signing the consent form - People who have been diagnosed with advanced skin melanoma (stage 3b through stage 4) that cannot be surgically removed or has spread, confirmed by laboratory testing of tissue samples - People whose melanoma...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06265025 · GeneMedicine Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 May 2025
🇰🇷 KR

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of signing the consent form. - People who have been diagnosed with a solid tumour that has spread, cannot be surgically removed, has not responded to previous treatment, or has spread to other parts of the body. - People wh...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06270706 · Pliant Therapeutics, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2030
🇺🇸 US

Who might be able to join this trial: - People who have been confirmed by laboratory testing to have an advanced or spreading solid tumour cancer. - People who have received at least 12 weeks of continuous treatment with a type of immunotherapy drug (known as an anti-PD-1 or anti-PD-L1 therapy), either on its own or co...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06272864 · BostonGene Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 8 January 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with one of the following cancers: breast cancer that has come back, cannot be surgically removed, or has spread to other parts of the body; non-small cell lung cancer that is at an advanced stage (Stage III) and cannot be surgically removed, or has...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06281678 · Innovent Biologics (Suzhou) Co. Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2026
🇺🇸 US

**Who might be able to join this trial:** - You are able to understand and sign a written consent form agreeing to take part in the trial and all its tests and procedures - You are 18 years old or older (male or female) - You are able to carry out normal daily activities with little to no limitation (rated 0 or 1 on a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06284590 · Philogen S.p.A. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older who give written consent to participate (or have a legal representative do so on their behalf). - People who have been confirmed through laboratory testing to have melanoma that cannot be surgically removed and has spread, at certain stages of the dis...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06295159 · H. Lee Moffitt Cancer Center and Research Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older who have been diagnosed with melanoma (skin, acral, mucosal, or from an unknown primary site) at a specific stage of disease, as classified by a standard cancer staging system. - People who have not previously received any systemic (whole-body) treatm...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06298734 · Fred Hutchinson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with melanoma (confirmed by a tissue/biopsy test) - You have been receiving immunotherapy for at least one month, or are just starting immunotherapy - You are planned to continue immunotherapy for at least 8 weeks fro...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06319196 · University Health Network, Toronto Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 February 2027
🇨🇦 CA

**Who might be able to join this trial:** - People aged 18 or older at the time of screening (or the legal age of consent in their country). - People who are willing and able to provide written consent before any study procedures begin. - People with a general health and activity level rated as fully active or restric...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06332755 · LG Chem Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 November 2027
🇺🇸 US

**Who might be able to join this trial:** - You must be 18 years of age or older when you sign the consent form. - *(Phase 1a only)* You must have been diagnosed with one of these advanced or spreading cancers: non-small cell lung cancer, head and neck cancer, kidney cancer, bladder cancer, or melanoma. - *(Phase 1a o...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06359860 · Beijing Scitech-Mq Pharmaceuticals Limited Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older - People with a life expectancy of at least three months - People who have been diagnosed (confirmed by laboratory testing of tissue or cells) with unresectable or metastatic stage III or IV acral melanoma (a type of melanoma found on palms, soles, or...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06363591 · Vastra Gotaland Region Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2034
🇸🇪 SE

Who might be able to join this trial: - People who have recently been diagnosed with an early-stage skin melanoma that is no deeper than 1.0 mm into the skin, confirmed by a full surgical removal and laboratory analysis of the tissue. - People whose melanoma is in a location on the body where surgery to remove a 10 mm...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06365619 · University of Utah Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older. - People with a confirmed diagnosis of advanced or metastatic melanoma (Stage IIIB-D or Stage IV) that has come back, and where a surgical specialist has determined the tumour can be removed or potentially removed. - People whose melanoma came back a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06384053 · Kantonsspital Winterthur KSW Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇨🇭 CH

Who might be able to join this trial: - You must sign and date a written consent form agreeing to take part in the trial - You have been diagnosed with a type of skin cancer that is not melanoma — specifically basal cell carcinoma (BCC) or squamous cell carcinoma (SCC), confirmed by a tissue sample (biopsy) - Your skin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06400550 · University of Texas Southwestern Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2028
🇺🇸 US

Who might be able to join this trial: - People aged 18 or older of any race or ethnic background who have known or suspected malignant melanoma lesions that need to be surgically removed or biopsied. Who may not be able to join: - People who are not considered suitable candidates for surgery. - People whose diabetes i...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06413680 · Regeneron Pharmaceuticals Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 3 February 2030
🇺🇸 US

**Who might be able to join this trial:** - People taking part in the dose escalation part of the trial must have a confirmed cancer diagnosis (advanced or spread to other parts of the body) that has continued to grow despite standard treatment. Providing stored tumour tissue samples is required if they are available....

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06414590 · Thomas Jefferson University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older at the time of signing consent forms - People who are able to read, understand, and sign a consent form before any study procedures begin - People who are willing to have tumor tissue samples (biopsies) taken before and after treatment with the study drug...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06418204 · Wake Forest University Health Sciences Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 August 2028
Puerto Rico🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older and have been recently diagnosed with breast cancer, colorectal cancer, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer. - You are scheduled to receive chemotherapy (one or more drugs, including targeted therapy) and/or a type of i...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06425926 · Georgiamune Inc Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have given written consent to participate - People who have a confirmed locally advanced or metastatic solid tumour (cancer that has spread) that has continued to grow despite standard treatment, for which no standard treatment exists, or where standard treatment...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06428721 · Wright State University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2031
🇺🇸 US

**Who might be able to join this trial:** - You are a man or woman aged 60 or older - You have at least 5 but no more than 10 actinic keratoses (rough, scaly skin patches that can be pre-cancerous) on each forearm or wrist area - You have fair skin (the type that tends to burn easily in the sun rather than tan) - Women...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06439979 · University of Utah Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2029
🇺🇸 US

**Who might be able to join this trial:** **Parents/Guardians:** - Adults who have children aged 3 or older playing on sports teams in rural areas of Utah or West Virginia - Adults who live and/or work in rural communities in Utah or West Virginia (as classified by standard rural coding systems) **Coaches and Team Le...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06466434 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People who speak English - People with a body mass index (BMI) between 18.5 and 45 - People whose cancer has not significantly limited their ability to carry out daily activities (this is measured using a standard scale called ECOG — confirm with tri...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06472661 · University of Virginia Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 August 2026
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older. - People who have been diagnosed with advanced melanoma and are planned to have surgery to remove the tumour. - People whose tumour(s) can be seen clearly on an ultrasound scan, measure at least 1 cm across, sit between 5 mm and 23 mm below the skin...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06488365 · Cytoastra Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 11 February 2026
🇺🇸 US

Who might be able to join this trial: - People who have a confirmed diagnosis of melanoma, based on a tissue sample examined in a lab. - People who have gone through the full informed consent process and signed a consent form, after having all study requirements and possible risks explained to them. - People who are ab...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06488482 · Uppsala University Phase 3 · 3 countries Recruiting
Recruiting Phase 3 Est. completion 1 September 2030
🇫🇮 FI🇳🇴 NO🇸🇪 SE

Who might be able to join this trial: - People who are willing and able to provide written consent to take part. - People who are 18 years of age or older. - People who are in good general health and able to carry out normal daily activities with little or no limitation (assessed using a standard health performance sca...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06500455 · NRG Oncology Phase 3 · 4 countries Recruiting
Recruiting Phase 3 Est. completion 30 June 2028
🇨🇦 CA Hong Kong🇮🇪 IE🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with one of these cancers, confirmed by laboratory testing of a tissue or cell sample within the past 5 years: non-small cell lung cancer, melanoma, breast cancer, renal cell carcinoma (a type of kidney cancer), or gastrointestinal cancer. If t...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06508775 · Miltenyi Biomedicine GmbH Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2040
🇩🇪 DE

Who might be able to join this trial: - People who received a Miltenyi CAR T cell therapy as part of a previous related clinical trial, at least 12 months before joining this follow-up study - People who have given their informed consent before enrolling in the study Who may not be able to join: - There are no exclusi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06519266 · Vastra Gotaland Region Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2028
🇸🇪 SE

**Who might be able to join this trial:** - You are 18 years of age or older - You have agreed to take part and signed a consent form - You are generally well enough to carry out light activity and care for yourself (confirm with trial site if unsure about your activity level) - Your uveal melanoma (a type of eye cance...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06545682 · M.D. Anderson Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 3 August 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older. - People who are willing and able to give their informed consent to participate. - People who have been confirmed by tissue testing to have advanced melanoma or triple-negative breast cancer (TNBC) that cannot be surgically removed, h...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06548789 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People with a body mass index (BMI) between 18.5 and 45 (a measure of body weight relative to height) - People who are able to complete study questionnaires tracking their diet and digestive symptoms on their own - People with a good to fully active...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06550674 · Centre Jean Perrin Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2028
🇫🇷 FR

Who might be able to join this trial: - People who have a personal history of uveal melanoma (a type of eye cancer), whether newly diagnosed, currently being treated, or in a follow-up phase - People who are enrolled in or receiving benefits from a social security scheme Who may not be able to join: - People who have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06560905 · Royal Marsden NHS Foundation Trust Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇬🇧 GB

**Who might be able to join this trial:** - You are male and 18 years of age or older - You have been diagnosed with melanoma (skin cancer) that has spread to other parts of the body (either for the first time or as a return of the disease), confirmed by a biopsy - You have swollen lymph nodes that can be felt by touch...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06586593 · Centre Hospitalier Universitaire de Besancon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2025
🇫🇷 FR

Who might be able to join this trial: - People who have melanoma that has spread (stage III or IV) but where surgery was considered an option, and who have been treated with a type of immunotherapy (a treatment that helps the immune system fight cancer) before surgery was planned - People whose immunotherapy response h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06594991 · Memorial Sloan Kettering Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of giving consent - People who are able to give informed consent themselves, or who have a legally authorised representative who can do so on their behalf - People who have been diagnosed with advanced or metastatic melanom...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06602648 · University of Florence Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇮🇹 IT

Who might be able to join this trial: - People who are under 20 years old (children and adolescents) or young adults under 30 years old - People who have a confirmed diagnosis of melanoma (a type of skin cancer) or a related borderline skin growth condition, verified through laboratory tissue testing Who may not be ab...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06605417 · Fundacion Clinic per a la Recerca Biomédica Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 31 March 2026
🇫🇷 FR🇪🇸 ES

**Who might be able to join this trial:** - You have a birthmark (a type of pigmented skin mark present from birth) that is estimated to be 20 cm in size - You are 18 years of age or older **Who may not be able to join:** - There is no biological material (such as tissue or blood samples) available from you for the st...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06605443 · Fundacion Clinic per a la Recerca Biomédica Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇪🇸 ES

Who might be able to join this trial: - You must be over 18 years old - You must have been diagnosed with melanoma (a type of skin cancer) that has been confirmed by a laboratory test, at stage II, III, or IV Who may not be able to join: - You are not willing or able to sign the consent form agreeing to take part in t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06608420 · Fundacion Clinic per a la Recerca Biomédica Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇪🇸 ES

Who might be able to join this trial: - You have been diagnosed with melanoma (a type of skin cancer), confirmed through a tissue sample test (biopsy) - People of any age can take part Who may not be able to join: - You do not have a confirmed diagnosis of melanoma - You have not signed the consent form agreeing to ta...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06621810 · German Cancer Research Center Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 30 November 2026
🇩🇪 DE🇮🇹 IT🇪🇸 ES

Who might be able to join this trial: - The inclusion criteria were not specified, so please contact the trial site directly to find out if you may qualify (confirm with trial site) Who may not be able to join: - People who have not been diagnosed with melanoma (a type of skin cancer) or a nevus (a mole or birthmark)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06624644 · Linnaeus Therapeutics, Inc. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 February 2029
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with skin melanoma (a type of skin cancer) that cannot be removed by surgery and/or has spread to other parts of the body. - Your body has two copies of a normally working version of a specific gene related to a protein called GPER (confirm with trial...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06626516 · Thomas Jefferson University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2030
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed (through a tissue or cell sample) with uveal melanoma (a type of eye cancer) that has spread to the liver, with at least one liver tumour measuring 10mm or more on a CT or MRI scan. Spread to other areas of the body is...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06627244 · University of Miami Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 17 February 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have metastatic uveal melanoma (a type of eye cancer that has spread) that is located mainly in the liver, confirmed by a pathology review - People whose liver function blood test results fall within specific acceptable ranges — serum bilirubin below 2 mg/dL, and...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06630611 · Vall d'Hebron Institute of Oncology Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2029
🇪🇸 ES

**Who might be able to join this trial:** - People who have been diagnosed (confirmed by lab testing) with metastatic or inoperable skin melanoma, non-small cell lung cancer (NSCLC), or cervical cancer that has grown or spread after at least one standard cancer treatment, or where standard treatment is not an option....

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06636435 · Chiome Bioscience Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 June 2027
🇯🇵 JP

**Who might be able to join this trial:** **Parts 1–4 (Adults):** - People who give their own written agreement to take part in the study voluntarily - People who are generally well enough to carry out light activity or desk work (a standard health scoring system rates them at 0 or 1 out of 5) - People whose kidneys a...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06643286 · Erasmus Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇳🇱 NL

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with cutaneous (skin) melanoma at stage I or stage II within the last 0 to 4 months Who may not be able to join: - People who have stage III melanoma that cannot be removed by surgery, people who are receiv...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06651151 · Oslo University Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2026
🇳🇴 NO

**Who might be able to join this trial:** - People aged 18 or older at the time of signing the consent form. - People with a laboratory-confirmed diagnosis of stage III or stage IV (M1a) melanoma that a specialist team has agreed can be fully removed by surgery and is suitable for treatment before surgery. - People wh...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06660420 · M.D. Anderson Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2029
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older. - People who are willing and able to give informed consent to participate. - People who have a specific genetic marker called HLA A\*02:01 (a blood test can confirm this). - People who have been diagnosed with advanced, inoperable, or...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06666790 · DermaSensor, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 11 April 2027
🇺🇸 US

**Who might be able to join this trial:** - You are a man or woman of any ethnic background, aged 40 or older - You have a skin spot or mole that a doctor suspects could be melanoma (a type of skin cancer) - You are willing and able to read, understand, and sign a consent form agreeing to take part **Who may not be ab...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06673095 · OHSU Knight Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇺🇸 US

Who might be able to join this trial: - A written consent form must be signed by the participant or their legally authorised representative before any study procedures begin - Adults aged 18 or older of any gender identity or racial/ethnic background are eligible - The participant must have a confirmed diagnosis of pri...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06675643 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 March 2027
🇺🇸 US

**Who might be able to join this trial:** - People with any type of skin cancer or melanoma who are starting a combination treatment of two immunotherapy drugs called ipilimumab and nivolumab together **Who may not be able to join:** - People who do not meet the inclusion criterion listed above **Important: Always ve...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06680323 · University Hospital Tuebingen Not Applicable · 5 countries Recruiting
Recruiting Not Applicable Est. completion 31 May 2025
🇩🇪 DE🇮🇹 IT🇵🇱 PL🇪🇸 ES🇸🇪 SE

Who might be able to join this trial: - People who have a confirmed diagnosis of melanoma (a type of skin cancer) - People who are 30 years old or younger Who may not be able to join: - People for whom no biological material (such as a tissue sample) is available for the study - People who have not signed an informed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06685562 · Leiden University Medical Center Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 20 May 2026
🇩🇰 DK🇳🇱 NL🇪🇸 ES

Who might be able to join this trial: - People who are over 18 years old, either as a patient or as an informal caregiver (such as a family member or friend involved in the care of a patient) - People who have been diagnosed with prostate cancer, breast cancer, or melanoma, or who are an informal caregiver for someone...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06703398 · Shanghai Juncell Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 10 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have signed the consent form and are able to follow the study schedule and requirements - People aged 18 to 75 years, of any gender - People diagnosed with advanced, returning, or spreading melanoma that cannot be surgically removed (uveal melanoma, a type that st...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06708663 · Hangzhou Hanx Biopharmaceuticals, Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part voluntarily and sign a consent form - Men or women aged between 18 and 70 years (inclusive) - People whose doctors expect them to live for at least 12 weeks - People who are fairly active and able to care for themselves, with little or no...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06712927 · Stanford University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with non-uveal melanoma (a type of skin or mucous membrane cancer, not eye melanoma) that has spread to the brain, with at least one brain tumour measuring between 5 and 40mm that has not previously been treated with targeted radiation (called...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06727630 · Zhuhai Yufan Biotechnologies Co., Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with advanced (unable to be surgically removed) or metastatic melanoma (skin cancer that has spread), confirmed by a lab test, whose cancer has come back or gotten worse after at least one previous treatment — note that eye (uveal) melanoma does...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06739226 · Shenzhen Geno-Immune Medical Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2028
🇨🇳 CN

Who might be able to join this trial: - People with melanoma who have already received standard first-line treatment and whose cancer cannot be surgically removed, has spread to other parts of the body, has progressed, or has come back. - People whose melanoma tumour tissue has been tested and confirmed to show specif...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06754904 · D.J. (Dirk) Grünhagen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇳🇱 NL

Who might be able to join this trial: - People aged 16 years or older - People who have been diagnosed with stage III melanoma (specifically stage IIIB, IIIC, or IIID) that has spread to one or more nearby lymph nodes, confirmed by laboratory testing of tissue samples - People whose melanoma is considered surgically re...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06765850 · Technische Universität Dresden Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇩🇪 DE

Who might be able to join this trial: - People who have been diagnosed with melanoma, either currently or in the past - People who are currently receiving treatment or follow-up care for a tumour at the Skin Cancer Centre at Dresden University Hospital Who may not be able to join: - People who do not wish to take part...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06767332 · Leiden University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2025
🇳🇱 NL

Who might be able to join this trial: - People who score 16 or higher on a specific fear of cancer recurrence questionnaire called the FCRI-NL-SF - People who are 18 years of age or older - People who have been diagnosed with familial melanoma (a hereditary form of skin cancer) Who may not be able to join: - People wh...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06771544 · University of California, Irvine Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇺🇸 US

Who might be able to join this trial: - People aged 18 or older at the time of signing the consent form - People who have been diagnosed with advanced melanoma (Stage III or Stage IV) that cannot be surgically removed and is not a type that starts in the eye, and where local treatments are not suitable - People whose c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06783270 · Inge Marie Svane Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 January 2027
🇩🇰 DK

**Who might be able to join this trial:** - People who have been confirmed by biopsy to have melanoma that cannot be surgically removed or has spread to other parts of the body (stage IIIc or IV). - People whose melanoma has continued to grow or spread after receiving standard immunotherapy treatments (anti-PD-1 thera...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06794775 · Hildur Helgadottir Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 15 April 2032
🇸🇪 SE

**Who might be able to join this trial:** - Adults aged 18 or older - People who are able to give written agreement to participate, following all the study rules and requirements - People with a good general health and activity level, rated 0 or 1 on the WHO Performance Status scale (meaning fully active or able to ca...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06797297 · Innovent Biologics (Suzhou) Co. Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 March 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been confirmed by lab testing (biopsy or cell sample) to have a type of melanoma called mucosal or acral melanoma that cannot be surgically removed, has spread to nearby areas, or has spread to other parts of the body (stage III or IV). - People who have not...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06805825 · Novelty Nobility, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 August 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed (confirmed by lab testing of tissue or cells) with one of these cancer types that is advanced, has spread, or cannot be removed by surgery: GIST (gastrointestinal stromal tumour), small cell lung cancer (SCLC), adenoid cystic carcinoma (ACC), uveal...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06828822 · Nantes University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 July 2031
🇫🇷 FR

Who might be able to join this trial: - The child must be under 2 years old. - The child must have a medium, large, or giant congenital nevus (a type of birthmark present from birth) — either one or more — as classified by a specific medical system called the Krengel classification. - The child must be covered by socia...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06831071 · Yana Najjar Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2029
🇺🇸 US

**Who might be able to join this trial:** - People who are willing and able to sign a written consent form for the study. - People who have been diagnosed with melanoma (confirmed through a tissue sample) for which their doctor has recommended a Sentinel Lymph Node Biopsy (a procedure to check nearby lymph nodes for c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06839105 · Shanghai Junshi Bioscience Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 April 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of signing the consent form, of any gender - People who have been diagnosed with an advanced cancer that has been confirmed by laboratory tissue or cell testing, and who meet specific requirements depending on which phase o...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06861023 · Centre Hospitalier Universitaire de Nice Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2025
🇫🇷 FR

Who might be able to join this trial: - You have had surgery to remove a large area of your nail and surrounding tissue on a finger or toe due to a type of skin cancer called acral melanoma, and then had reconstructive surgery either straight away or at a later date. Who may not be able to join: - You have had a finge...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06880198 · Fondazione Melanoma Onlus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇮🇹 IT

**Who might be able to join this trial:** - Adults aged 18 or older. - People who have been diagnosed with skin melanoma (cutaneous melanoma) that is either at an advanced stage that cannot be surgically removed (stage III unresectable) or has spread to other parts of the body (stage IV), confirmed by tissue testing....

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06887088 · Grupo Español Multidisciplinar de Melanoma Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇪🇸 ES

**Who might be able to join this trial:** - People who have given written agreement to participate before any trial activities begin. - People who have been confirmed by laboratory testing to have melanoma that cannot be removed by surgery, has spread to other parts of the body (stage IV), and has one or more tumours...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06889610 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2027
🇨🇳 CN

**Who might be able to join this trial:** **Criteria that apply to all groups:** - Adults between 18 and 80 years old, any gender - People who have liver tumours that can be treated with ablation (a procedure that destroys tumour tissue), where all liver tumours are smaller than 5 cm across - People with an expected s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06889766 · Centre Hospitalier Universitaire Vaudois Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2029
🇨🇭 CH

Who might be able to join this trial: - People who have been diagnosed with advanced or metastatic skin melanoma, or any type of sarcoma, confirmed by a tissue sample analysis. - People with sarcoma who have already tried at least one standard treatment that did not work, stopped working, or caused intolerable side eff...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06899789 · Fondazione IRCCS Policlinico San Matteo di Pavia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇮🇹 IT

Who might be able to join this trial: - You must be 18 years old or older - You must be able to give your consent to participate, or in some cases your existing data may be used for the research portion of the study (rules may vary by country) - You must have received at least one round of a type of cancer treatment ca...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06906822 · Grupo Español Multidisciplinar de Melanoma Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇪🇸 ES

**Who might be able to join this trial:** - People aged 18 or older who have been diagnosed with melanoma that cannot be surgically removed or has spread to other parts of the body, confirmed by laboratory testing of tissue. - People whose cancer can be measured on scans according to standard criteria (called RECIST v...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06932757 · University of Miami Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 27 May 2030
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with uveal melanoma (a type of eye cancer) where the tumour measures at least 12 mm across at its widest point, as assessed by their treating doctor. - People whose main treatment for uveal melanoma (such as surgery or radiation) was completed withi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06942143 · Guangzhou FineImmune Biotechnology Co., LTD. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 25 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing and able to sign a consent form before any trial activities begin - You are between 18 and 75 years old (male or female) - Your cancer has not responded to your first round of treatment (first-line treatment has failed) - Your cancer has at least one measurab...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06946225 · Immatics US, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 August 2029
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with either cutaneous melanoma (skin cancer) or synovial sarcoma (a type of soft tissue cancer) that cannot be surgically removed or has spread to other parts of the body - People who have tested positive for a specific immune system marker cal...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06961357 · H. Lee Moffitt Cancer Center and Research Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2029
🇺🇸 US

**Who might be able to join this trial:** - People who have been confirmed by laboratory testing to have melanoma that cannot be surgically removed (Stage III/IV) or that has spread to other parts of the body — including common skin melanoma, acral melanoma (found on palms, soles, or nail beds), mucosal melanoma (foun...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06965231 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years old or older - You are reasonably active and able to care for yourself with little or no help with daily activities (confirm with trial site) - You have been diagnosed with skin or acral (hands/feet) melanoma that has been confirmed by a tissue or cell sampl...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06967961 · Institut Claudius Regaud Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 July 2029
🇫🇷 FR

**Who might be able to join this trial:** - People diagnosed with one of these specific cancer types: bladder/urinary tract cancer (urothelial carcinoma), kidney cancer, prostate cancer, cancers of the mouth/throat/upper airway area, cervical cancer, uterine (endometrial) cancer, skin melanoma, soft tissue sarcoma, or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06970236 · University of Valencia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇪🇸 ES

Who might be able to join this trial: - Adults who have been diagnosed with Choroidal Melanoma (a type of eye cancer) and are being treated with a specific radiation therapy called plaque brachytherapy at the Hospital Universitari i Politècnic La Fe in Valencia, Spain. Who may not be able to join: - People whose curre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06980740 · University Hospital Muenster Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2026
🇩🇪 DE

**Who might be able to join this trial:** - People aged 18 years or older - People who have given written consent to take part in the study - People who, in their doctor's opinion, should be reviewed by a specialised skin cancer team (tumor board), particularly those with one of the following: - Malignant melanoma a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06985056 · Universität Duisburg-Essen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇩🇪 DE

Who might be able to join this trial: - People aged 18 or older who have been diagnosed with malignant melanoma (Stage IIb to IV) and are currently receiving immunotherapy or targeted therapy, either to reduce the chance of cancer returning or to manage advanced disease - People whose general physical functioning falls...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06994208 · Ente Ospedaliero Ospedali Galliera Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇮🇹 IT

Who might be able to join this trial: - Adults who have given written consent to take part in the study - People between the ages of 18 and 40 years old - People who have been diagnosed with cutaneous melanoma (a type of skin cancer), including cases that did not start in the skin originally Who may not be able to joi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07027488 · Yale University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 August 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older at the time they sign the consent form. - People who are able to give written consent to take part in the study. - People whose general health and ability to carry out daily activities meets a specific performance level (rated 0 or 1 o...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07031830 · University Hospital, Rouen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 November 2028
🇫🇷 FR

**Who might be able to join this trial:** - People aged 18 or older, of any gender - People who have advanced melanoma that has been treated with immunotherapy or targeted therapy, either to prevent recurrence or as a curative treatment - People who have read and understood the study information letter and do not objec...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07042243 · University of Florida Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇺🇸 US

**For Patients:** Who might be able to join this trial: - People who are 18 years of age or older - People who have received a confirmed cancer diagnosis (colorectal, prostate, lung, breast, gynecologic, blood-related, or skin cancer including melanoma) within the past 12 months - People who are able to read and speak...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07050940 · Azienda Ospedaliera di Perugia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇮🇹 IT

Who might be able to join this trial: - Adults aged 18 years or older. - People who have been diagnosed with advanced melanoma (stage IIIC or IV) that cannot be surgically removed, confirmed by a tissue sample test. - People who are generally well enough to carry out daily activities with little or no limitation (based...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07057596 · Grupo Español Multidisciplinar de Melanoma Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇩🇪 DE🇪🇸 ES

**Who might be able to join this trial:** - People who have been diagnosed with metastatic uveal melanoma (a type of eye cancer that has spread) confirmed by tissue testing, and whose blood test shows a specific genetic marker called HLA-A\*0201. - People whose uveal melanoma has spread to the liver in a way that surg...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07070518 · GV20 Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 16 July 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 years or older - People who have an advanced solid tumour cancer that has been confirmed by laboratory tissue testing, has continued to grow or spread, and has already been treated with standard cancer treatments (or who could not tolerate those treatments) -...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07099430 · Nanjing Leads Biolabs Co.,Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 October 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to follow the trial's treatment plan, attend all scheduled visits, complete required tests, and sign a consent form agreeing to take part - You are 18 years old or older (any gender) - You are generally well enough to carry out light activity and care for your...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07106827 · West China Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 11 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have voluntarily agreed to take part by signing a consent form before any study procedures begin - People who are able and willing to follow all study procedures for the full duration of the trial - People who have an adva...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07112170 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 24 July 2027
🇨🇦 CA

Who might be able to join this trial: - People aged 18 or older - People whose general health and ability to carry out daily activities falls within a certain range (a medical score called ECOG 0–2 — confirm with trial site what this means for a specific situation) - People who are willing and able to give informed con...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07130032 · EuroCityClinic LLC Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 14 August 2025
🇷🇺 RU

Who might be able to join this trial: - Adults aged 18 or older - People who are well enough to carry out daily activities with little to no limitation (based on a standard medical scale called ECOG, scoring 0 to 2) - People who have been diagnosed with either non-small cell lung cancer (NSCLC) or skin melanoma that h...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07136181 · Novelwise Pharmaceutical Corporation Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 March 2028
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with metastatic uveal melanoma (a type of eye cancer that has spread), confirmed by a tissue or cell sample - Your cancer can be measured on a scan, following standard medical guidelines - You are well enough to carry o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07144306 · Nuvana Healthcare LTD Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇬🇧 GB

Who might be able to join this trial: - Adults aged 18 or older who have a skin lesion that a doctor suspects may be cancerous. - People who are able to give their informed consent to take part in the trial. Who may not be able to join: - People who are unable to give their informed consent to take part. - People whos...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07148245 · University of California, San Francisco Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇺🇸 US

Who might be able to join this trial: - You must be 18 years old or older - You must be able to speak and read English - You have been diagnosed with stage IIB, III, or IV melanoma (a type of skin cancer) - You are scheduled to receive at least one immune checkpoint inhibitor treatment (a type of cancer drug that helps...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07155317 · Emory University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed through laboratory testing with advanced (stage IV) melanoma that cannot be surgically removed, specifically of the skin surface, hands/feet/nails (acral), or mucous membranes (such as the mouth or nasal passages) - People whose melanoma has spread...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07160335 · Shanghai Henlius Biotech Phase 1 · 4 countries Recruiting
Recruiting Phase 1 Est. completion 30 April 2027
🇨🇳 CN🇬🇪 GE Turkey (Türkiye)🇺🇸 US

**Who might be able to join this trial:** - People who have signed a written consent form approved by an ethics committee, agreeing to take part in the study. - People aged 18 to 85 years old at the time of signing the consent form. - People whose body weight is between 50 kg and 85 kg, and whose body mass index (BMI)...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07161310 · Goethe University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇩🇪 DE

**Who might be able to join this trial:** - People who have been recently diagnosed with a solid tumour cancer and have not yet received any systemic (whole-body) cancer treatment - People whose doctors have planned a first-line standard treatment using one or two immune checkpoint inhibitor medicines, with or without...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07170293 · Tianjin Medical University Second Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2027
🇨🇳 CN

**Who might be able to join this trial:** *(Note: The source document provided only exclusion criteria. Inclusion criteria were not listed. Please confirm what is required to qualify with the trial site directly.)* --- **Who may not be able to join:** - You have been diagnosed with another cancer in the past 2 year...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07177937 · Hangzhou DAC Biotechnology Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 20 October 2030
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to sign a consent form and follow the study requirements - People of any sex (male or female) - For most solid tumour patients: people aged 18 to 75 years; for prostate cancer patients: people aged 18 or older with no upper age limit - People whose doc...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07193966 · Shenzhen Geno-Immune Medical Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2028
🇨🇳 CN

Who might be able to join this trial: - People whose cancer has already received standard first-line treatment and has been confirmed as unable to be removed by surgery, has spread to other parts of the body, has continued to grow, or has come back. - People whose tumor has been tested and shows positive expression of...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07201376 · Dartmouth-Hitchcock Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older. - People who have been diagnosed with a type of skin cancer called non-melanoma skin cancer, confirmed by a tissue sample test, and are already scheduled to have the growth removed. - People with any skin tone (the trial includes a range of skin tones bas...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07206017 · University Medical Center Groningen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 March 2026
🇳🇱 NL

**Who might be able to join this trial:** - Adults aged 18 or older - People who understand the study and are able to sign a written consent form - People who have had surgery for an intermediate to high-risk skin melanoma at a specific stage, with no sign of the disease remaining after surgery (confirm with trial site...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07215182 · Barbara Malene Fischer Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 20 August 2026
🇩🇰 DK

Who might be able to join this trial: - Adults aged 18 or older, of any gender - People who have been diagnosed with melanoma (a type of skin cancer) that has spread to other parts of the body or has grown into surrounding tissue, confirmed by a tissue sample - People whose cancer can be detected on specialist medical...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07215988 · Ohio State University Comprehensive Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with one of the following cancers, confirmed by a pathology report at the time of screening: Merkel cell carcinoma, mucosal melanoma, basal cell carcinoma, or certain rare skin cancers (squamous cell carcinoma) - People aged 18 or older - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07221734 · mAbxience Research S.L. Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 1 April 2027
🇵🇹 PT🇺🇦 UA

**Who might be able to join this trial:** - People who are 18 years of age or older (or the legal age of adulthood in their country) at the time of signing the consent form. - People who weigh at least 50 kg at the start of the trial. - People who have signed a consent form before any trial-related procedures begin. -...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07224425 · Boehringer Ingelheim Phase 1 · 3 countries Recruiting
Recruiting Phase 1 Est. completion 5 October 2029
🇧🇪 BE🇳🇱 NL🇺🇸 US

Who might be able to join this trial: - People with a confirmed solid tumour diagnosis (Part A) who have already tried all available treatments known to help their condition, or for whom no proven treatment options exist. - People with a confirmed solid tumour diagnosis (Part B) whose cancer has continued to grow or wh...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07225036 · Jordan Kharofa Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 June 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People whose general health and ability to carry out daily activities meets a minimum level, as assessed by standard medical scoring tools (confirm with trial site) - People whose heart, liver, kidneys, and other organs are functioning well enough to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07230613 · UNICANCER Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇫🇷 FR

Who might be able to join this trial: - People aged 18 or older. - People who have a type of melanoma (skin or mucosal) that is at stage III, can be surgically removed, and is measurable using standard imaging guidelines. - People who previously received a type of immunotherapy called anti-PD-1 treatment, as long as th...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07237100 · Kevin Kim, MD Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 13 October 2027
🇺🇸 US

Who might be able to join this trial: - People who have melanoma that cannot be surgically removed or has spread to other parts of the body, and whose tumour has a confirmed NF1 gene mutation (tested at an approved certified laboratory — variants of unknown significance do not qualify) - People who have had NF1 gene se...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07237594 · Duke University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 June 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with advanced melanoma that has spread to other parts of the body, confirmed by a tissue test. - People aged 18 or older at the time of signing the consent form, of any gender. - People whose treating doctor has planned for them to receive a ty...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07251335 · University of Modena and Reggio Emilia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇮🇹 IT

Who might be able to join this trial: - People who are patients at the Dermatology Clinic at the University Hospital of Modena. - People who are 18 years of age or older. - People who have had a dermatological check-up for a suspected skin lesion. - People who are able to understand and sign a consent form written in I...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07260591 · The First Affiliated Hospital of Xinxiang Medical College Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have given their voluntary written consent to participate - People aged 18 years or older - People who have an advanced solid tumour (such as melanoma, head and neck cancer, cervical cancer, bone cancer, nasopharyngeal carcinoma, breast cancer, lung cancer, colore...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07266142 · Universitaire Ziekenhuizen KU Leuven Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2050
🇧🇪 BE

"Who might be able to join this trial: - You must be willing to give your agreement to take part before any screening takes place, either yourself or through someone legally authorised to act on your behalf. - You must be 18 years of age or older at the time of joining the trial. - You must have been diagnosed with eit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07276386 · H. Lee Moffitt Cancer Center and Research Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2030
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older at the time of signing the consent form - People who are generally well enough to carry out normal daily activities with little to no limitation (a measure doctors use called ECOG performance status 0 or 1) - People who have been confirmed...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07277920 · University of Modena and Reggio Emilia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇮🇹 IT

Who might be able to join this trial: - People who are 18 years of age or older - People who have skin lesions that have been examined using specialised skin imaging tools (dermoscopy and reflectance confocal microscopy) and are suspected to be a type of mole or pigmented skin growth, and who already have surgery sched...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07280715 · University of Pittsburgh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - People who have started immune checkpoint inhibitor therapy for melanoma within the last three months at UPMC Hillman Cancer Center - People who are 18 years of age or older - People who are able to read and write in English - People who own and regularly use a smartphone that ca...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07280832 · Shanghai JMT-Bio Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 November 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 years or older. - People with melanoma that has been confirmed by a tissue or cell sample, and that cannot be surgically removed, has spread locally, or has spread to other parts of the body. - For the earlier phases of the trial (Phase I and Phase IIa): peopl...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07281924 · University of Wisconsin, Madison Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2030
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with melanoma that has spread to the liver, confirmed by a liver biopsy showing melanoma cells. - You have not yet received systemic (whole-body) treatment for your advanced or metastatic melanoma — although previous adjuvant (preventive) treatment wit...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07287917 · Aminex Therapeutics, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 February 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older at the time of signing the consent form. - People diagnosed with certain advanced or spreading solid tumours that cannot be surgically removed — specifically, hormone receptor-positive (ER+), HER2-negative breast cancer (Group 1) or melanoma (Group 2)...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07288112 · Diakonos Oncology Corporation Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2031
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 years or older - People diagnosed with melanoma that cannot be surgically removed or has spread to other parts of the body, and whose cancer has continued to grow or spread after at least one previous treatment that included an anti-PD-1 therapy (a type of imm...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07302607 · University Hospital, Strasbourg, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2026
🇫🇷 FR

**Who might be able to join this trial:** - People aged 18 or older - People diagnosed with advanced melanoma (stage III or stage IV that cannot be removed by surgery), classified according to a standard medical staging system - People who received a type of cancer treatment called immunotherapy (specifically treatment...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07310758 · The Netherlands Cancer Institute Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 18 September 2026
🇳🇱 NL

Who might be able to join this trial: - You are 18 years old or older - You have been diagnosed with cancer in the skin (melanoma), breast, or head and neck area (including melanoma in the head and neck) - If you have melanoma, it must be located on the arms, legs, or in the head and neck area - You are already schedul...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07310784 · Suzhou BlueHorse Therapeutics Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old, either male or female, at the time of signing the consent form - People whose doctors expect them to survive for more than 3 months - People who are relatively active and able to care for themselves (a medical scoring system called ECOG rates...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07336979 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 20 March 2027
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 or older - People who have been diagnosed with resectable mucosal melanoma, confirmed through laboratory analysis of tissue samples - People who are able to provide 5 stored tissue samples taken before treatment, or who are willing to have a needle biopsy to collec...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07349303 · Vastra Gotaland Region Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 May 2029
🇸🇪 SE

**Who might be able to join this trial:** - People aged 18 or older. - People who are willing and able to give signed consent to participate. - People who are generally well enough to carry out daily activities with little to no limitation (as measured by a standard medical scale called ECOG, with a score of 0 or 1)....

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07349940 · Institute of Health Information and Statistics of the Czech Republic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇨🇿 CZ

"Who might be able to join this trial: - People who have at least one area of skin that is suspected to be an abnormal or concerning spot or growth - People with skin type I or skin type II (these are the lightest skin tones, which burn easily and rarely or never tan) Who may not be able to join: - People who have had...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07354152 · Nantes University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇫🇷 FR

Who might be able to join this trial: - You are 18 years old or older (male or female) - You have been diagnosed with skin melanoma at any stage (Stage I, II, or III) before having surgery - After surgery to remove the melanoma with clear margins, the wound left behind is too large to be closed in a straightforward way...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07376707 · Hefei TG ImmunoPharma Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 October 2027
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 or older at the time of signing the consent form. - People with a confirmed diagnosis (from a tissue or cell sample) of an advanced or spreading solid tumour cancer that cannot be surgically removed — including, but not limited to, colorectal cancer (CRC), liver ca...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07379138 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2031
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed with stage III or stage IV melanoma within the last 2 months or less - People who can read English well enough to complete a survey and an informed consent form Who may not be able to join: - People who do not meet t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07400302 · The First Hospital of Jilin University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2029
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to give written consent and are willing and able to follow the trial visit schedule and procedures. - People who have been confirmed through laboratory testing (from a tissue sample) to have mucosal melanoma, where all known primary and/or spread-related...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07404605 · Institute of Oncology Ljubljana Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2025
🇸🇮 SI

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed with skin melanoma confirmed by a laboratory tissue test - People who have melanoma that has spread to the skin or just beneath the skin, in a way that is suitable for a treatment called electrochemotherapy - People w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07407166 · Institute of Oncology Ljubljana Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇸🇮 SI

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed with metastatic (spreading) melanoma, a type of skin cancer that has spread to other parts of the body - People who are planning to start their first course of immunotherapy treatment for this condition - People who a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07415564 · University of Arizona Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇺🇸 US

**Who might be able to join this trial:** **For cancer survivors:** - People aged 18 or older - People who have been diagnosed with stage IV (metastatic) breast cancer, gastrointestinal cancer, or melanoma - People who are able to carry out basic day-to-day activities on their own - People who are aware of who they ar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07422779 · Institute of Oncology Ljubljana Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2027
🇸🇮 SI

**Who might be able to join this trial:** - People aged 18 or older - People whose melanoma has spread (metastatic) and has been confirmed through a tissue or cell sample test - People whose melanoma is classified as stage IIID (cannot be surgically removed) or stage IV, according to a standard cancer staging system ca...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07445022 · Fudan University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 September 2028
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 or older, of any gender - People with melanoma (a type of skin cancer) that has spread to nearby tissue or other parts of the body, confirmed through a laboratory test of a tissue or cell sample - People whose cancer test results show a specific genetic change call...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07448831 · Universitair Ziekenhuis Brussel Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2026
🇧🇪 BE

**Who might be able to join this trial:** - You must be 18 years of age or older at the time of signing the consent form - You have been diagnosed with a specific type of high-risk skin melanoma, confirmed by a tissue sample (biopsy), that falls into certain risk categories based on tumour thickness and/or a special t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07449754 · Hanmi Pharmaceutical Company Limited Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2029
🇰🇷 KR

**Who might be able to join this trial:** - People who have been diagnosed with melanoma that has spread locally or to other parts of the body, confirmed by laboratory testing of tissue or cell samples, and for whom standard treatments have not worked, are no longer working, or cannot be tolerated - People whose melano...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07501117 · Inge Marie Svane Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2029
🇩🇰 DK

Who might be able to join this trial: - Adults aged 18 to 80 years old - People who can read and understand Danish - People who have been diagnosed with uveal melanoma (a type of eye cancer) that has not yet been treated, is localised to the eye, and is classified as high risk (T3 or T4 stage), with surgery to remove t...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07504796 · NYU Langone Health Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 May 2029
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older. - People who are willing and able to attend scheduled visits, complete lab tests, and follow the study requirements. - People diagnosed with advanced melanoma that cannot be surgically removed, classified as stage IIIB through stage IV (including cer...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07511933 · The Netherlands Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇳🇱 NL

Who might be able to join this trial: - You must be willing and able to sign a consent form agreeing to take part in the trial - You must be 18 years old or older - You must be well enough to carry out some daily activities (a general health score will be assessed) - You must have a measurable brain lesion of at least...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07530887 · Marieke Goodijk Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 November 2033
🇳🇱 NL

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of giving consent - People whose general health and ability to carry out daily activities falls within a certain range, as measured by a standard medical scoring tool called the ECOG scale (scores 0–2, meaning fully active...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07562841 · West China Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 April 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older. - People whose general physical condition is rated as fully active or able to carry out light work (as measured by a standard oncology scale called ECOG, with a score of 0 or 1). - People with a confirmed diagnosis of melanoma that cannot be surgical...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07564570 · Universitätsklinikum Hamburg-Eppendorf Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇩🇪 DE

Who might be able to join this trial: - People who have been diagnosed with metastatic malignant melanoma (melanoma that has spread to other parts of the body) that has been confirmed through laboratory testing of tissue samples, and for whom a type of immunotherapy treatment (the drugs Nivolumab and Ipilimumab) has be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07584226 · Relay Therapeutics, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 December 2027
🇺🇸 US

Who might be able to join this trial: - People whose overall health and ability to carry out daily activities falls within a certain range, measured by a standard scale called ECOG, with a score of 0 (fully active) or 1 (restricted in strenuous activity but able to do light work). - People who have been confirmed by la...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07584291 · Xijing Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with acral melanoma (a type of melanoma affecting the hands, feet, or nails) or cutaneous melanoma (melanoma of the skin), based on established melanoma diagnosis guidelines - People who have previously had a sentinel lymph node biopsy (a proced...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07586891 · Xijing Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with Stage III melanoma (a type of skin cancer that has spread to nearby lymph nodes or nearby areas of skin), confirmed by a tissue or cell sample from a lab. - People whose melanoma started in the skin (those with melanoma starting in the eye or i...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07586904 · Xijing Hospital Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 75 years of age, of any gender, who are willing to take part and sign a consent form. - People whose melanoma has been confirmed by a tissue or cell sample (biopsy) to be either stage III or a specific type of resectable (surgically removable) stage IV....

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07600476 · Kupando GmbH Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2028
🇩🇪 DE

**Who might be able to join this trial:** - You have been diagnosed with cancer (confirmed by laboratory testing of tissue) that has spread or is advanced, and there are no other standard treatments available for you. - You are generally able to carry out daily activities, either fully, or with some limitations but sti...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07628634 · University of California, Irvine Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 May 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 years or older. - People who have been diagnosed with solid tumours that have spread, come back, or cannot be surgically removed. - People with a life expectancy of at least 3 months. - People who are well enough to carry out basic daily activities, as measured by...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07635732 · Medical University of Graz Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2028
🇦🇹 AT

Who might be able to join this trial: - People who have melanoma that requires treatment with systemic (whole-body) therapy - People who are 18 years of age or older - People who are willing and able to give informed consent to take part in the study Who may not be able to join: - People who are unable to give informe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07644897 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 May 2027
🇨🇳 CN

Who might be able to join this trial: - People aged 60 years or older - People who have been diagnosed with malignant melanoma, confirmed through a tissue or cell sample examination - People whose melanoma has been classified as advanced (unresectable stage III or stage IV) according to standard medical staging guideli...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07680699 · AC Camargo Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇧🇷 BR

Who might be able to join this trial: - Adults aged 18 or older who have been diagnosed with skin melanoma (a type of skin cancer), confirmed through a tissue sample, at a specific stage — either Stage IIB, Stage IIC, or Stage III (N1c) — and who are being treated as part of normal, everyday medical care. Who may not...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Melanoma. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

Melanoma Patients Australia (MPA) is the national patient advocacy body. Melanoma Institute Australia and the Australian Melanoma Research Foundation are clinical and research organisations rather than patient advocacy groups, but may be useful if you are looking for treatment or research information.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.